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ABSTRACT 
POLYMERIC PEPTIDE MIMICS FOR PROTEIN DELIVERY 
 
MAY 2018 
 
CORALIE M. BACKLUND, B.S., OREGON STATE UNIVERSITY 
 
M.A., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Gregory N. Tew 
 
 
 
The plasma membrane is a major obstacle in the development and use of 
biomacromolecules for intracellular applications. Consequently, proteins with intracellular 
targets represent an enormous, yet under studied avenue for therapeutics. Extended 
research has aimed at facilitating intracellular delivery of exogenous proteins using protein 
transduction domains (PTDs), which allow transport of bioactive molecules into cells. 
Synthetic polymers, inspired by PTDs, provide a well-controlled platform to vary 
molecular architecture for structure activity relationship studies. Specifically, this thesis 
focuses on the use of ring-opening metathesis, a facile and efficient polymerization 
technique, through which we can vary structural parameters to optimize delivery of non-
covalently encapsulated proteins. The aim was to characterize, optimize, and utilize PTD 
mimics (PTDMs) for functional protein delivery. Fluorescently labeled cargo were used to 
elucidate the predominant cellular entry mechanism for the PTDMs and were compared to 
their ability to deliver protein into cells. A series of polymers was designed around the 
most membrane active polymers to explore the incorporation of guanidine and hydrophobic 
moieties, yielding a PTDM capable of high protein delivery into a variety of cell types. The 
PTDM was then explored for use as a vaccine delivery reagent into immune cells. The 
 vii  
ability to have a specific response with the cargo of interest verifies cytosolic delivery using 
the PTDMs and provides valuable insight into their use to affect intracellular pathways.  
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CHAPTER 1 
INTRACELLULAR DELIVERY OF FUNCTIONAL PROTEINS 
1.1 Introduction 
Proteins and antibodies have the capacity to perform specific and complex 
functions making them promising candidates to probe molecular pathways within cells. 
Most proteins that would facilitate these specific interactions are generally incapable of 
passive diffusion across the cell membrane due to their size and polarity. Additionally, 
physical and chemical changes extracellularly and intracellularly can alter a proteins 
function via hydrolysis, oxidation, proteolysis, and denaturation.1 To address these issues, 
a wide variety of delivery methods and vehicles have been designed for transporting and 
protecting these complex cargos.  
Historically, introducing exogenous protein into the cell has been accomplished 
indirectly by delivering DNA that will express the protein of interest into the cell or by 
controlling protein synthesis through the delivery of RNA.2 Despite the utility of these 
approaches, direct protein delivery has several advantages over recombinant genetic 
approaches. Instead of genetically manipulating cells to express a protein of interest, which 
can result in random insertion and mutation of endogenous genes, protein delivery allows 
for temporal control into specific areas of the cell. The delivery of proteins like Cre 
recombinase and the CRISPR-Cas9 system allow for specific gene editing with high 
specificity and low toxicity.3,4 The transient nature of the protein within the cell also means 
that the amount of protein and its function can be controlled and is not indefinite. In 
comparison with small molecule drugs, the targeted effect can be exceptionally specific, 
such as in the case of using antibodies to promote or interrupt intracellular pathways.5  
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Currently, the overarching term attributed to methods of protein delivery is 
transduction which is rooted in its use for viral delivery of genetic material. While the field 
of protein transduction began with the use of physical membrane disruption such as 
electroporation and microinjection, it has shifted more towards the use of lipids, peptides, 
and synthetic nanocarriers to facilitate the transport of proteins across the membrane.6 
Additionally, a variety of inorganic carriers are also being developed as theranostic 
delivery reagents.7–9 An overview of these methods is provided, with specific attention on 
their ability to deliver functional proteins into cells.  
The major design principles of nanocarriers are three-fold: they need to (a) package 
and protect cargo, (b) deliver the protein intracellularly, and (c) release payload with 
appropriate spatiotemporal dynamics. One of the major areas of debate for transduction is 
the mechanism through which these carriers cross the membrane.6,10,11 The mechanism of 
cellular entry directly dictates the availability of the cargo within the cell. If most of the 
nanocarrier assemblies are taken up through endocytosis, the cargo must overcome the 
endosomal membrane before being readily available in the cytosol or nucleus.  
The field of nanocarriers is extremely complex and correct definitions of each 
carrier type are essential for comparing to other systems within the same class and for the 
translation of essential concepts to the next generation of carriers.12 Here, we propose 
classification guidelines to help define carrier types. Although some overlap between the 
different categories is possible, as indicated in Figure 0.1, usually the distinction is clear 
enough to choose a predominant label.  
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Figure 0.1. Categorization and progression of nanocarrier based protein delivery 
from viral transfection to synthetic nanocarriers. The circumference of the circle 
roughly indicates the volume of research directed toward protein delivery. 
The scope of this introduction is to explore the methods that facilitate the transport 
of functional proteins across the cell membrane with special attention to nanocarrier types. 
While many methods explore protein delivery using fluorescently labeled cargo, the focus 
here is largely on in vitro experiments with functional protein cargo that has some 
measurable intracellular biological activity. This introduction highlights the current 
approaches to functional protein delivery along with the existing challenges and offers 
some perspective into future directions for the field.  
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1.2 Physical Delivery Methods 
1.2.1 Microinjection 
Microinjection involves the use of a glass micropipette to deliver foreign material 
with extremely precise spatial and temporal control into a variety of cell types.13,14 A 
schematic of a single cell being microinjected is shown in Figure 0.2. Since the only 
exogenous material is the controlled amount of injected substance, it is theoretically the 
only independent variable in well controlled experiments.15 Microinjections can be 
performed directly into both the cytosol and the nucleus, requiring much less protein than 
electroporation or carrier based methods.14 Additionally, specific cell types can be 
transduced without using targeting motifs. Dosage of multiple cargos can also be controlled 
with current models of air-pressure-driven micro-injectors, which allow fine tuning of 
injection pressure and timing.14  
 
Figure 0.2. Single cell microinjection for introduction of exogenous proteins. Figure 
adapted from By KDS444 via Wikimedia Commons (left) and Stewart et. al.6 (right).  
Microinjection has been extensively used in studies with primary human neurons, 
since they are difficult to transfect by other methods. Several examples of functional 
protein delivery exist including recombinant caspases, heat shock protein 70 (Hsp70), and 
antibodies.16–19 
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Direct microinjection of recombinant active enzyme capsase-6 induces a protracted 
course of apoptosis in neurons. The results show that active caspase-6 induces significant 
cell death in neurons but not in astrocytes, where caspase-3 triggers cell death in astrocytes 
and not in neurons.16 
Amyloid-b (Ab), an intracellular peptide related to Alzheimer’s disease is 
extremely toxic to human primary neurons when injected into the cytosol but not when 
applied in culture medium suggesting intracellular Ab may contribute to cell death more 
significantly than extracellular Ab.17 Co-microinjection of Hsp70 with intracellular Ab 
blocks the toxicity of the Ab suggesting that estrogens and androgens protect neurons 
against Ab toxicity by increasing the levels of Hsp70.  
Microinjection of antibodies was used to study the importance of actin filaments 
for the regulation of gap junctional intracellular communication in astrocytes.19 The 
injection of the antibody reduced spreading of neurobiotin suggesting that the actin 
cytoskeleton is involved in the regulation of intracellular communication. 
Although microinjection has low cytotoxicity, only a few hundred cells can 
reasonably be transduced at a time limiting the overall efficacy of this technique.16,17 
Positive controls and immune-histochemical staining can be used to detect the transduction 
of injected proteins. Additionally, with division, delivered proteins will be diluted out with 
each cell cycle resulting in a lower readout for the injected protein in rapidly dividing cell 
types. Lastly, the injection causes physical stress to the membrane of the cell. Therefore a 
vehicle control is required to monitor assess the effect of the injection on viability.20  
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1.2.2 Electroporation 
Electroporation uses an electric field to create short-lived pores through the cell 
membrane, which allow external molecules to cross.6,21 Membrane disruption, as 
illustrated in Figure 0.3, allows small and large molecules such as antibodies, proteins, and 
DNA to be delivered through these reversible pores. There are several advantages to 
electroporation including its ease of use, as well as avoidance of endosomal entrapment. 
Additionally, it eliminates the cytotoxicity associated with foreign materials in the cases of 
chemical transduction or viral infection.  
 
Figure 0.3. Membrane disruption leading to transient pores that allow protein to be 
delivered into the cytosol of cells. Illustration adapted from Steward et. al.6 
Traditionally, a solution with suspended cells is dispersed between parallel plates 
that apply a series of electrical pulses of determinable voltage, frequency, and duration.21 
Microfluidic designs offer the ability to localize the electric field to the scale of the cell, 
reducing the required voltage, and providing better heat dissipation.6,22 
A notable example is the transduction of Cas9:sgRNA complexes via 
electroporation into primary human hematopoietic stem cells and T cells resulting in 
specific nucleotide insertions in the CXCR4 and PD-1 surface receptor genes.23 Direct 
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protein delivery via electroporation improved efficiency and reduced off target effects 
compared with endogenous expression of Cas9.23,24 Other examples of proteins that have 
been transduced into a variety of lymphoid cells include cytochrome c, caspase-8, and 
granzyme B, all which showed functional status in the major apoptosis pathway of intact 
cells.25  
When compared directly with a lipid-based system, transduction of rEGFP was 
approximately 10% at 18 hours after electroporation compared with about 20% efficiency 
from the lipid based system.26 Increased voltage and protein concentration increased 
transduction efficiency, though never exceeded 30% in the study. While efficiency can be 
high for electroporation depending on the size of the cargo, it also results in membrane 
damage leading to excessive cell death, especially with sensitive cell, such as primary 
cells.27 Additionally, the electric field can have detrimental effects such as aggregation and 
denaturation on both the biomolecules being delivered, as well as endogenous cellular 
proteins.28,29  
 
1.2.3 Microfluidics 
Cytosolic delivery has also been reported using rapid mechanical deformation on a 
microfluidic platform.30 As the cell passes through a constriction with a minimum 
dimension smaller than the cell diameter, as seen in Figure 0.4, it results in the formation 
of transient pores.31 The size and frequency of the pore is dependent on the shear and 
compressive forces caused by the microfluidic channel. The pores allow for material from 
the surrounding media to diffuse into the cytosol and cells can be processed at a rate of 
20,000 cells/s.31  
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Figure 0.4. Membrane disruption using microfluidic squeezing. The intact cell is 
passed through a narrow channel which causes pores to form allowing exogenous 
protein (yellow) to cross the membrane. Image adapted from Stewart et. al.6 
Transcription factors (Oct4, Sox2, c-Myc, and Klf-4) were delivered to human 
fibroblasts yielding higher levels of protein expression compared with other delivery 
methods that rely on endocytosis.31 Cytoplasmic delivery of quantum dots can also be 
achieved using high throughput microfluidic devices.32 
Microfluidic membrane disruption has most recently been use to load antigens into 
polyclonal B cells for use as cellular vaccines.33 Post transduction, the B cells elicited 
robust priming of effector cells in vitro conferring cytosolic delivery OVA protein 
indicating successful transduction. Higher flow rates result in higher uptake, but also cause 
higher cytotoxicity. Microfluidics is only useful for transducing cells in suspension and has 
lower overall efficiency than Lipofectamine, but it does result in higher levels of cytosolic 
delivery.31  
1.2.4 Insight 
Physical membrane disruption addresses many challenges associated with protein 
delivery. Traditionally, key weaknesses of membrane disruption strategies have been the 
inconsistent extent of plasma membrane injury from cell-to-cell. In general, these methods 
render insufficient delivery and cause excessive cell damage. Membrane disruption also 
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suffers from poor throughput or scalability, loss of cytoplasmic content, and slow cell 
recovery resulting in inefficient protocols.6 Methods that employ electric fields may 
denature proteins or damage cell components and many physical disruption techniques also 
require cells to be in suspension.  
 
1.3 Lipid-Based Nanocarriers 
1.3.1 Liposomes 
Conventional liposomes are composed of phospholipids and cholesterol, forming a 
spherical vesicle with one or more bilayers (Figure 0.5). For several decades, liposomal 
carriers have been widely used for the delivery of various biomolecules including proteins, 
antibodies, peptides, and nucleic acids either through encapsulating cargo in the liposome 
or embedded it on the membrane surface.34–37 The liposomal bilayer stabilizes the cargo by 
preventing degradation and facilitates internalization into cells generally through 
incorporation of cationic charge in the lipid membrane. Compatibility of constituent lipid 
components with the cell membrane make liposomes attractive for many applications.34,38  
 
Figure 0.5. A simplified representation of liposomes that have one or more lipid 
bilayers with an aqueous core, and solid lipid nanoparticles which have a solid 
hydrophobic core.  
Cellular uptake of liposomes is generally believed to be mediated by endocytic 
processes resulting in entrapment in endosomal compartments within the cell.39 To 
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overcome the endosomal barrier, several strategies have been used including pH sensitivity 
and the addition of cell penetrating peptides to the surface of the liposome.40  
An example of functional protein delivery mediated by a cationic lipid is the use of 
RNAiMAX™ to deliver CRISPR-Cas9 proteins along with their single guide strand RNA 
with over 50% gene editing efficiency.3 Another bio-reducible lipid system has also shown 
delivery of the CRISPR-Cas9 complex and subsequent genome editing.41  
Liposomes with protein suspended in the membrane, known as proteoliposomes, 
have also been used to deliver mitochondrial VDAC and Bak, which are important stimuli 
in the release of cyt-c and caspase activation, ultimately resulting in apoptosis.36 A potent 
primary CTL response against soluble protein can be achieved through the delivery of 
antigen, such as OVA, in pH-sensitive liposomes to dendritic cells.42 Efficient MHC class 
I presentation of antigens has also be shown using liposomes decorated with octa-
arginine.35,43 
Liposomal systems are widely studied and tend to be a benchmark in the field of 
biomolecule delivery due to their tunability and ease of use. In addition to their high 
endosomal entrapment, liposomal preparation methods which use solvents, sonication, and 
detergents can lead to protein denaturation and loss of activity. High cellular toxicity may 
also occur due to treatment in the serum free conditions which are required for efficient 
delivery, making liposomes an unfavorable candidate for sensitive cell types such as 
primary cells.44  
 
1.3.2 Solid Lipid Nanoparticles 
Solid lipid nanoparticles (SLNs) are submicron colloidal particles with a rigid core 
composed of hydrophobic solid lipids stabilized by an emulsifying layer in an aqueous 
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dispersion (Figure 0.5). In general, SLNs are solid at room or body temperature and both 
hydrophobic and hydrophilic proteins can be incorporated or adsorbed to their surface 
resulting in improved stability and sustained release of the cargo.45 The main factors 
influencing peptide and protein release from solid lipid particles are the physiochemical 
characteristics of the loading, particle size, lipid matrix composition, and choice of 
surfactants.46 Functional proteins including insulin, somatostatin, and thymocartin have 
been incorporated into SLNs through solvent evaporation, micro-emulsion, or melt 
dispersion with varying rates of loading and subsequent release.47,48  
The hydrophilic nature of most proteins reduces their ability to be 
microencapsulated into the hydrophobic matrix of SLNs as they tend to partition in the 
water phase during the emulsion preparation.46 Additionally, processing conditions can 
lead to aggregation or denaturation of cargo like their liposome counterparts. Lipid carriers 
with several lipids and emulsifying agents generally exhibit low cytotoxic effects in vitro 
compared with their polymeric counterparts, even at high concentrations. The cytotoxicity 
of SLNs can be mainly attributed to components of the aqueous phase, especially non-ionic 
emulsifiers and preservatives.49 
1.3.3 Insight 
Although protein encapsulation within lipid delivery systems can protect peptides 
and proteins from proteolytic enzymes, low protein loading efficiency and slow endosomal 
escape remain major hurdles for lipid delivery systems. Due to their synthetic simplicity 
and wide spread use, lipid-based carriers remain one of the most predominant carriers in 
the field of delivery. In the future, we can expect an increasing number of lipid-based 
carrier systems, especially for proteins with poor aqueous solubility. 
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1.4 Inorganic Nanocarriers 
1.4.1 Carbon Nanotubes 
Carbon nanotubes (CNTs) are cylindrical allotropes of carbon that have a long 
hollow structure with walls formed by a single layer of carbon, also known as graphene. 
Their orbital hybridization imparts distinct properties including exceptional strength and 
allows for an exceptionally high length to diameter ratio.50,51 CNTs offer several appealing 
features such as large surface areas with well-defined physical and chemical properties, as 
well as unique optical and electrical properties.52 Biomolecules can be conjugated non-
covalently or covalently to the surface, helping to reduce their toxicity and 
immunogenicity.50–54 While there have been significant advances in the field of CNT-based 
drug delivery, there are only a few examples of biomolecules being delivered into cells. 
Kam et al. delivered streptavidin, a protein with clinical applications in anticancer 
therapies, conjugated to single walled nanotubes (SWNTs) into 3T3 fibroblasts, CHO, 
HL60, and Jurkat T cells, showing uptake through endocytosis. Additionally, they report 
streptavidin concentration dependent cytotoxicity, but negligible cell death caused by the 
SWNTs without streptavidin.51  
Experiments exploring the binding, intracellular transporting, and release of 
cytochrome c (cyt-c) with SWNT carriers were carried out in an investigation of biological 
function. Due to its low molecular weight, SWNTs have a high loading of cyt-c, which is 
known to activate apoptosis and activity was monitored using Annexin V staining. HeLa 
and NIH-3T3 cells showed increased rates of apoptosis in the presence of cyt-c SWNTs 
suggesting that cyt-c was still functional after being transported into the cell.55  
Additional reports have investigated functionalization with peptide chains to show 
delivery of shorter sequences. Although peptide function is not explicitly demonstrated, 
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high levels of cell death are shown after delivery of a peptide known to block the beta 
adrenergic receptor conjugated to CNTs.54 
CNTs face challenges regarding (1) synthesis: purity, bioconjugation, 
functionalization, and modification that allow biocompatibility; (2) a thorough 
understanding of mechanism and interaction with cells; (3) development of toxicity 
guidelines and analysis; and (4) demonstration of advantages compared with existing 
technologies.50 Cytotoxicity associated with CNTs remains a major concern both in vitro 
and in vivo. Conflicting reports may be attributed to variability in the dose, purity, 
functionalization, cell type, and treatment methods.50 The use of metal catalysts remains 
the main source of cytotoxicity followed by their tendency to aggregate.51,54 More 
guidelines and systematic testing are required to determine toxicity and the life cycle of 
functionalized CNTs within cells to further their viability for use in biomolecule delivery.  
1.4.2 Quantum Dots 
Quantum dots (QDs) are nanocrystals on the order of 2 to 10 nm made of 
semiconducting materials that can fluoresce to produce distinctive colors dependent on the 
size of the particle.56 The distribution of colors and sizes are shown in Figure 0.6A. Due to 
their small size, QDs have been widely used as fluorescent probes to visualize biological 
processes both in vitro and in vivo due to their narrow tunable emission spectra, excellent 
thermal stability, and resistance to photo-bleaching.57  
The delivery of QDs and their protein cargos can be roughly divided into passive 
endocytosis or carrier facilitated uptake, the latter of which involves conjugation to a 
peptide, protein, or polymer.58,59 Most QD-protein conjugates without an endosomal 
escape motif are distributed in endosomal compartments making their cargo not readily 
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accessible in the cytosol.57 QDs are not the most efficient functional protein nanocarrier, 
but do allow for dynamic tracking and detection of exogenous proteins and peptides within 
cells.60 
QD-based transduction has been explored using the exogenous thin filament protein 
cardiac troponic C (cTnC) into myofibrillar cells.61 To facilitate membrane crossing and 
endosomal escape, a peptide linker TAT-HA2 was conjugated to the QD-cTnC. 
Internalization and distribution through the cell, specifically in association with myofibrils, 
as seen in Figure 0.6B, was achieved with post-functionalization with the peptide.  
 
Figure 0.6. (A) Color dependence on size of QDs. (B) QDs (red) co-localized with 
myofibrils (green) within a cell. Figure adapted from Zrazhevskiy et. al.57and 
Koshman et. al.61 
Intracellular delivery of QD-protein conjugates is highly dependent on the nature 
of the QD itself, as well as the cell type being investigated. Current techniques to 
functionalize QDs are dependent on the QD and are not easily translatable across cargos.62 
Additionally, conjugation as well as a shift in pH can increase the size of the QD 
substantially.62 The toxicity of QD materials also remains a concern, arising from the 
semiconducting metals.63 While there have been many accomplishments in the 
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development of controlled delivery of QDs into cells, progress in functionalization and 
cytotoxicity will help propel the use of QDs as visualization aids in cell culture. 
1.4.3 Gold Nanoparticles 
Gold nanoparticles (AuNPs) are easily functionalized yet bio-inert, facilitating 
cellular imaging with low cytotoxicity.64,65 Similar to QDs, AuNPs require surface 
functionalization with cationic amines or peptides to promote endocytosis, or antibodies 
for receptor mediated endocytosis. Alternatively, reports of citrate capped AuNPs have 
also shown internalization by cells, possibly caused by protein adsorption.66  
Recently, spherical hierarchical self-assemblies between proteins and AuNPs have 
been used to deliver functional proteins into cells.67,68 Proteins were tagged with an oligo-
glutamic acid (E10), which can self-assemble with arginine functionalized AuNPs 
resulting in direct cytosolic delivery of proteins with a variety of sizes and charges into 
mammalian cells while maintaining their function. Most notably, Cre recombinase, a gene 
modifying protein, was delivered into a LoxP modified human embryonic kidney cells 
resulting in knockout of an RFP gene and subsequent expression of GFP after 48 hours.69 
Additionally, granzyme A, a cytolytic enzyme produced by cytotoxic T cells, was delivered 
into HeLa cells via the same strategy, resulting in caspase 3/7 mediated cell death.67  
In terms of vaccine development, Wang et. al. designed a multivalent antigen and 
adjuvant co-delivery platform using both click chemistry and chelation of AuNPs to attach 
the cargo.64 Both types of conjugation induced production of pro-inflammatory cytokines 
and led to antibody production against the delivered antigen. AuNPs have also been used 
to deliver recombinant human VEGF, where the protein was attached by the thiol group of 
cysteine residues.70 HUVECs treated with the AuNP-VEGF proliferated substantially 
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faster than those without the growth factor. While functionalization or protein modification 
is required, gold nanoparticles provide a useful tool for in vitro delivery, as well as 
intracellular imaging for protein tracking and dynamics. 
1.4.4 Silica Nanoparticles 
Mesoporous silica nanoparticles (MSNs) are prepared by an assembly of silicates 
and surfactant, in which the pore size and structure are easily controlled by the co-assembly 
conditions. In general, MSN materials have large surface areas and pore volumes and can 
by endocytosed by mammalian cells making them effective delivery vehicles for the 
controlled release of biomolecules.71–73 Internalization studies suggest that the MSNs 
undergo nonspecific adsorptive endocytosis, and endosomal uptake was shown using FITC 
labeled cargos.74 The addition of amine or guanidine groups, such as cell penetrating 
peptides, enhances energy dependent uptake and promotes endosome escape.74,75  
To show functional protein delivery using MSNs, cyt-c was delivered into HeLa 
cells.76 The protein was loaded using a diffusion driven process based on concentration and 
controlled release was measured with a drop in pH consistent with that which occurs in 
lysosomes. Delivery into HeLa cells revealed release of the functional protein into the 
cytoplasm. Loading and release of the cyt-c relied on its interactions with the silica surface 
and may not be easily applied to other proteins. Another example of functional protein 
delivery was MSNs functionalized with n-octadecyltrimethoxysilane were loaded with 
Ribonuclease A and anti-phospho-Akt antibody, which were subsequently delivered into 
MCF-7 human breast cancer cells resulting in controlled apoptotic cell death. 77 
A recently developed system involves a breakable hybrid organo-silica-
nanocapsule where the protein cargo is encapsulated within a breakable hybrid shell 
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comprising of disulfide bridges embedded in a silica network.78 The cytotoxic protein 
human TRAIL Apo2 ligand and onconase were delivered into C6 glioma cells where the 
active proteins were released by breaking the shell of the capsule. However, as shown 
through co-localization between lysotracker and GFP, much of the protein cargo remains 
sequestered in lysosomes with very little being available in the cytosol.  
Although pores in MSNs can be used to encase proteins, there is a size limit 
restricting larger proteins from being successfully loaded and transported across the 
membrane.79 Progress in controlling pore size and morphology will facilitate 
immobilization of a larger variety of cargos.  
1.4.5 Magnetic Nanoparticles 
The ability to tune the surface of magnetic nanoparticles (MNPs) makes them 
multifunctional, allowing synthesis with a variety of cargos.80 Magnetically mediated 
protein delivery can enhance the therapeutic profile by increasing the localized 
concentration of target cargo and minimize non-specific interactions. Although MNPs have 
shown application in theranostics, there are very few cases of the use of MNPs for 
functional protein delivery in vitro.  
Intracellular delivery of MNPs loaded with catalase, an antioxidant enzyme, was 
confirmed through the rescue of target cells that were undergoing toxicity due to hydrogen 
peroxide.81 Experiments were performed in bovine aortic endothelial cells, where the 
MNPs were guided to these cells and increased their resistance to oxidative stress.  
Iron oxide nanoparticles have been shown to cause cell membrane injury in both a 
concentration and time dependent manner.82 Therefore, low concentrations of MNPs are 
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optimal to ensure mitigation of oxidative stress induced cell injury. Additionally, cargo 
must be functionalized to the MNP, potentially reducing the functionality of the protein. 
1.4.6 Insight 
Since inorganic nanoparticles are relatively new to the field of biomolecule 
delivery, many hurdles are still being addressed such as aggregation. Additionally, due to 
their inert nature many inorganic nanoparticles require functionalization with other 
delivery vehicles such as a cell penetrating peptide or cationic polymers to achieve 
internalization. The theranostic benefits of inorganics, especially when used as imaging 
agents has huge potential, but for now these particles are not able to deliver functional 
protein intracellularly.  
1.5 Protein and Peptide Mediated Carriers 
1.5.1 Engineered Proteins 
Supercharged proteins are a class of engineered or naturally occurring proteins with 
unusually high net positive or negative theoretical charge.83 The creation of supercharged 
proteins was first reported in 2007 as the product of extensive mutagenesis in which solvent 
exposed residues on the proteins surface are substituted with either acidic or basic amino 
acids.84 The functionality of these proteins is preserved, but reduced in some cases.83 Both 
positively and negatively supercharged proteins exhibit a remarkable ability to withstand 
thermal or chemical induced aggregation.84,85 Superpositively charged proteins are also 
able to penetrate mammalian cell membranes and have shown utility in enabling the 
delivery of functional proteins.83,85,86 
Positively supercharged GFP has been shown to deliver a variety of functional 
proteins directly into cells by translational fusion.85,87 Cre recombinase functioned as a 
general measure of delivery as its enzymatic activity is only observed by its presence in 
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the nucleus. In addition to Cre recombinase, functional delivery of the CRISPR-Cas9 gene 
editing system has been shown using supernegatively charged GFP in conjunction with the 
cationic lipid system RNAiMAX.3 The strategy for fusing functional proteins to the 
negatively charged GFP is illustrated in Figure 0.7.Recently, a diverse class of naturally 
occurring supercharged human proteins has been identified that potentially deliver 
functional proteins into mammalian cells.83  
 
Figure 0.7. Functionalization of active proteins with super-negatively charged GFP 
(A) for intracellular delivery using cationic lipids commonly used to deliver RNA and 
DNA (B). Image adapted from Zuris et. al.3  
In addition to supercharged proteins, intracellular delivery has been reported for 
engineered G proteins which contain a histidine affinity tag on the N- terminus and cell 
penetrating peptide sequence at the C-terminus.88 The engineered G protein allows for 
capture of surface modified nanoparticles and antibodies through non-covalent interactions 
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with the histidine tag and non-invasively delivers the complex into cells using the CPP. 
Delivery of both cargos independently and combined was demonstrated in Hela cells.  
The non-viral E2 subunit of pyruvate dehydrogenase has also been developed as a 
protein delivery platform.89,90 E2 is a caged protein made of self-assembling monomers to 
form a hollow capsule which can be post modified with proteins. E2 was shown to co-
deliver the MHC I restricted peptide SIINFEKL and CpG, an oligonucleotide into dendritic 
cells.89  
Supercharged proteins are an interesting, new class of protein delivery vehicles. 
Understanding how these proteins are able to cross the membrane would facilitate the 
development of specific targeted carriers. Additionally, movement away from covalent 
attachment would enable these proteins to be easily used with a variety of cargos.  
1.5.2 Exosomes 
Exosomes are a family of vesicles secreted by most cell types with a diameter in 
the range of 30-120 nm.91 The production of exosomes is a major route of cellular excretion 
allowing for the disposal for the removal of unwanted RNA and proteins and can also 
transport cargos between cells. Initially, an invagination of endosomal membranes creates 
a multi-vesicular body, they are then fused with the membrane and secreted.91 Exosomes 
have shown utility in therapeutics due to their low immunogenicity and toxicity but high 
biological permeability and biocompatibility.92 
Due to their intrinsic ability to carry endogenous proteins, exosomes seem to be 
suitable carriers for protein delivery. An example of this endogenous protein transfer was 
demonstrated by Shimoda et al. who reported the functional transfer of CagA into recipient 
cells inducing cell elongation.93 Recently, the gene editing protein Cre recombinase was 
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loaded into exosomes by exploiting the evolutionarily conserved late-domain and showed 
functional gene knockdown.94 
Loading and delivering small RNAs has been a major focus using exosomes for 
biological delivery.91 There have been only a handful of reports on successful packaging 
of macromolecular proteins into exosomes due to the major challenge of low loading 
efficiency.93–96 There is a need to explore more efficient protein loading approaches before 
exosomes will be widely applied for protein delivery.  
1.5.3 Virus Like Particles 
Virus like particles are derived from viral capsid proteins and resemble their native 
virus counterpart, but lack the genetic components.28,97,98 They can be assembled to 
encapsulate a variety of non-viral biomolecules including proteins and engineered to 
express and display heterologous proteins. Many viruses can be used as VLPs including 
murine leukemia virus, lentivirus, retrovirus, Sendai virus, and their ability to deliver 
bioactive proteins such as antibodies, transcription factors, and enzymes has been 
demonstrated in a variety of cell types.99–102 Although some viruses possess natural cell 
and tissue tropism,103 broad cell specificity is exhibited by many VLPs making them viable 
candidates for protein delivery into a variety of cell types.28 
Kaczmarczyk et. al. have shown that VLPs can be used to deliver a variety of 
functional proteins intracellularly, including Cre recombinase, cytotoxic enzymes, and 
human caspase 8.97 Protein ligands such as TRAIL and IFN-g can also be displayed on the 
outside of the VLP allowing for signaling control within cells during delivery.97  
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Similar to liposomes and exosomes, controlled loading of specific proteins into 
VLPs remains a challenge. Additionally, some knowledge of molecular biology is required 
to use this in a functional laboratory setting to load proteins of interest into the VLPs.  
1.5.4 Protein Toxins 
Plant and bacterial toxins can be potent inhibitors of intracellular processes and 
often contain their own translocation domain or complex.39,104 While some toxins exploit 
cellular machinery to enter cells such as the cholera toxin, others can form pores for 
cytosolic entry like anthrax and diphtheria.105–108 In general, pore forming toxins are an 
ensemble of an enzymatic moiety in conjunction with a cell surface receptor that mediates 
entry into the cytosol.104 These protein complexes can be exploited for protein delivery, 
though the toxins themselves can have detrimental effects on cellular function, as well as 
viability.104 
Anthrax has been shown to deliver a variety of cargos including peptides, proteins, 
and antibody-like molecules with varying degrees of success.105 Ballard et. al. modified 
cytotoxic T cell epitopes derived from bacteria with an anthrax derivative to create 
immunogenic response for mouse CD8 T cells.106 Additionally, the delivery of an antibody 
mimic into the cytosol of cells via conjugation with anthrax into has been demonstrated by 
co-immunoprecipitation of the affibody with its target, as well as interruption of several 
pathways.109  
Auger et. al. demonstrated that a variety of proteins could be delivered using the 
diphtheria toxin.110 The conjugation, targeting and endosomal escape of their strategy is 
depicted in Figure 0.8. To ensure that the protein cargo is functional after conjugation to 
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the diphtheria, alpha-amylase was delivered into HEK293 cells resulting in rapid glycogen 
degradation in treated cells.  
 
Figure 0.8. Diphtheria toxin can be conjugated to cargo and brought across the cell 
membrane through pH-driven pore formation releasing the cargo into the cytosol. 
Figure adapted from Auger et. al.110 
Biological toxins provide a facile delivery platform for biomolecules with diverse 
structures and functionalities due to the promiscuity of their pore forming units. 
Investigations by several groups have demonstrated that the cargo must be able to adopt an 
unfolded or extended conformation in the endosome and cargos with low pKa values that 
cannot be protonated in the endosome may inhibit translocation limiting the variety of 
cargo that can be efficiently transduced.105 Lastly, further exploration in to the 
immunogenicity and cellular effects of using toxins would provide more insight into the 
practical use as protein carriers. 
1.5.5 Cell Penetrating Peptides 
Initially introduced into the field of delivery over two decades ago, cell penetrating 
peptides have become a staple for the intracellular delivery of proteins and other 
biomolecules.111–113 The ability to transverse the membrane has transcended their use 
across a variety of systems including liposomes, engineered proteins, and polymers.113–115 
The hallmark discovery of HIV-1 Tat lead to the discovery and generation of an entire field 
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of short, cationic, and sometimes amphiphilic peptide sequences.11,112,116,117 These can be 
loosely divided into naturally occurring sequences such as Antennapedia homeodomain 
and MAP; chimeric mimics like transportan and penetratin; along with their synthetic 
peptide mimics including R9 and Pep-1. 11,118 
Intracellular delivery can be achieved through direct conjugation of cell penetrating 
peptides to the cargo requiring post modification of the desired cargo. Some studies have 
reported non-covalent complexing with the desired cargo.119–121 An inexhaustible list of 
protein delivery using cell penetrating peptides exists; a few highlights have been included 
here.  
R9 has been used in to co deliver covalently linked Cas9 protein along with guide 
strand RNA to show efficient knockdown by the functional ribonuclear protein complex.122 
Additionally, oligo arginine attached to zinc finger nucleases as well as TALEN proteins 
have also shown gene editing capabilities suggesting their presence in the nucleus with low 
cytotoxicity.123  
One major example of TAT and other CPPs is its use in delivering peptides and 
proteins for cancer treatments. Fusion of the apoptosis inducing protein apoptin to HIV-
TAT resulted in high transduction efficiency in all cell types, but only apoptosis in cancer 
cells after migration to the cytoplasm and nucleus.124 Other proteins include p53, anti-p21, 
and antitumor antibody fragments.125 TAT fusion proteins have also been shown to deliver 
hsp70, required for protection against glutamate dehydrogenase deficiency disorders.126,127  
Endosomal escape remains a major concern for many cell penetrating peptide 
systems. Akishiba et. al. demonstrated delivery of Cre recombinase, saporin, and IgG in 
addition to exosome encapsulated proteins using a modified endosomolytic peptide derived 
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from the spider venom.96 Cytosolic delivery of bioactive protein was confirmed with gene 
recombination by Cre recombinase. The delivered anti-glucocorticoid receptor IgG 
blocked intracellular signaling and transcription suggesting functional activity of the 
antibody in the cytosol.  
Conjugation of CPPs to biomolecular cargo has proven an effective tool for protein 
delivery, but there are still challenges within the field including toxicity, stability, and 
immune response.128,129 Additionally, post modification of the cargo with CPPs can 
influence the functionality of the protein within the cell.  
1.5.6 Insight 
Natural sources of protein delivery such as CPPs and VLPs provide a biological 
answer to protein delivery. Since all the components are naturally synthesized by cells, 
degradation products are of minimal concern making these systems extremely 
biocompatible. Like all delivery systems, some assembly is required and in many cases 
knowledge of molecular biology methods is useful to facilitate conjugation or entrapment 
of the protein.  
1.6 Synthetic Polymeric Nanocarriers 
1.6.1 Protein Transduction Domain Mimics 
Polymers can be used to mimic the functional transduction domains of proteins 
either by polymerizing cationic and hydrophobic monomers, or by incorporating active 
motifs into the backbone of the polymer chain.114,115 Several groups have developed 
systems for protein transduction domain mimics (PTDMs), also referred to as cell 
penetrating peptide mimics (CPPMs).130–132 
As a developing area of delivery, PTDMs have mostly been explored for uptake 
using a fluorescent label on the polymer itself. The Kolonko et. al. has demonstrated 
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cytosolic and endosomal uptake of FITC labeled artificial translocation domain.133 
Additionally, McKinlay et. al. show that uptake of guanidinium-rich oligophosphoesters is 
superior to their guanidinium-rich oligocarbonates and oligoarginines counterparts.131  
Using a norbornene based amphiphilic block copolymer, Sgolastra et. al. 
demonstrated non-covalent delivery of functional Cre recombinase into a human T cell line 
using PTDMs resulting in gene knockout.134 A similar polymer was used for delivery of 
functional anti-pPKCq into primary human lymphocytes enabling the perturbation of 
intracellular pathways to dictate cell fate.135  
Functional protein delivery has been shown for both covalent attachment as well as 
non-covalent delivery. While the polydispersity makes these systems difficult to fully 
characterize, they have shown promise in their ability to deliver proteins into cells at a 
higher efficiency than their peptide counterparts.136  
1.6.2 Nanogels 
Nanogels are a type of hydrogel on the order of 10-200 nm and are made of cross-
linked soluble polymer chains. They can be modified to encapsulate proteins or to 
covalently attach cargo to the surface. The porous nature of hydrogels allows controllable 
release kinetics of their cargo based on crosslinking density. During synthesis, no organic 
solvents or harsh fabrication techniques are required; polymers that have been most widely 
evaluated for the preparation of nanogels include poly(N-isopropylacrylamide) (pNIPAM), 
poly(lactic acid) PLA, poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), 
polyhydrobuterate, and polypropylene glycol.137,138 Biological materials like dextran, 
hyaluronic acid, and chitosan are also used to form nanogels.139 Nanogels, along with the 
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other nanocarriers described in this section have been illustrated in Figure 0.9 since many 
of them have similar components.  
 
Figure 0.9. Schematic of synthetic nanocarriers. 
Active enzymes, such as caspase-3, have been covalently attached to the surface as 
well as encapsulated inside polymeric redox sensitive nanogels through disulfide 
linkages.140 Further modification with a CPP is required for internalization, and activity of 
caspase-3 was restored upon cleavage from the nanogel in the reducing environment of the 
cell. 
Zhao et al. showed intracellular delivery of caspase-3 encapsulated in redox 
responsive nanogels which degrade at lowered pH due to their disulfide containing 
crosslinker. 141 Single encapsulation of the caspase-3 using the nanogel showed rapid 
uptake and trafficking into the cytosol, followed by induced apoptosis. Negative controls 
of the nanogel without the caspase-3 and the caspase-3 by itself showed low cytotoxicity 
in HeLa, U-87 MG, and MCF-7 cells.  
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Crosslinked nanoparticles were synthesized with a pH responsive PDEAEMA 
(polydimethyl amino ethyl methacrylate) core and hydrophilic PAEMA (polyazidoethyl 
methacrylate) charged shell to deliver OVA into dendritic cells.142 The hydrophobic pH 
buffering component facilitated endosomal disruption and cytosolic delivery resulting in 
elevated IFN-g production and cross presentation of antigen.  
There are several advantages to nanogels as protein carries, including their 
biocompatibility due to their high water content, biodegradability, high loading capacity, 
and tunable crosslinking densities which allows controlled cargo release.138 Additional 
modification can allow stimuli responsive release of cargo including degradation based on 
pH, temperature, or an applied electric field.8  
1.6.3 Polymeric Micelles 
The structure of amphiphilic molecules allows them to accumulate at the boundary 
of two non-miscible phases and to function as surfactants. With an increase in 
concentration, the free energy begins to rise and at the critical micelle concentration, the 
amphiphiles will self-assemble into colloidal sized particles illustrated in Figure 0.9.12 
Careful modulation of the relative block lengths and the composition of block copolymer 
affects the shape of the overall amphiphile, which affects the packing parameter, giving 
rise to micelles or higher order structures such as bilayers. Since assembly is a reversible 
process driven by thermodynamics, micelles are categorized as an amphiphilic colloid and 
not a solid nanoparticle.143 Proteins can be loaded inside the hydrophobic core of the 
micelle for use as a delivery vehicle.  
Coué et. al. describe a bioreducible poly(amidoamine) that associate with their 
protein cargo through charge reversibility.144 For this system, the charge density of the 
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protein of interest was temporarily increased by the modification of the lysine residues to 
make them negatively charged carboxylic groups resulting in a strongly anionic surface. 
The cationic block copolymers were then associated with the cargo for rapid delivery into 
the cytosol. The modifying groups on the lysines are redox sensitive, degrading at a pH of 
5.5 releasing the cationic polymer to allow endosomal escape. Functional antibody was 
stained for using a secondary antibody after cell fixation. Some activity was lost due to the 
initial modification, though presence was detected regardless of modification technique.  
Polymer micelles face some inherent problems including low stability in aqueous 
environments, low loading capacity, low cellular uptake compared with liposome and 
polymersome counterparts, toxicity correlated with an increase in polymer required to 
deliver high concentrations of cargo, immunogenicity, and short half lives in biological 
environments.12,139 
1.6.4 Dendrimers 
Dendrimers are a specific type of highly branched, globular macromolecules which 
are composed of many arms emanating from a central core.145 As depicted in Figure 0.9, 
the inner layers of the dendrimer have a homogeneous structure from every branch point 
stemming from the core. In some cases, dendrimers can be end capped with peripheral 
functional groups to change surface properties. The iterative nature of dendrimer synthesis 
leads to control over density and reactivity of surface functional groups, as well as control 
of overall size and molecular structure.146 
In general, hydrophobic therapeutic substances are loaded in the non-polar core of 
the dendrimer and both positively or negatively charged surface functional groups can be 
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used to complex with cargo.137 Only a few examples exist for protein delivery, and those 
are limited to cases of low numbers of protein bound per dendrimer.  
Bayele et. al. used lysine rich dendrimers to deliver c-Myc monoclonal antibody 
into HeLa cells.147 Dendrimers with guanidinium moieties at the end of each branch were 
capable of delivering the antibody IgG into HEp-2 cells.148 Cargo with measurable 
intracellular function was not used in either of these studies, rather fluorescence was used 
to track the uptake. The multivalency of dendrimers make them excellent at interacting 
with cell receptors and subsequently being internalized by cells, though there is still much 
to be explored in their use to deliver biological cargos.9,149 High cytotoxicity is associated 
with dendrimers after incubation for longer time periods.147  
1.6.5 Nanocapsules and Polymersomes 
Stable self-assembled polymeric shells are similar in morphology to liposomes in 
their colloidal nature with an outer layer made from amphiphilic block copolymers.12 
Depending on the polymeric component and the nature of the core, two variations exist: 
nanocapsules with an oily liquid core and a single outer layer of polymer and 
polymersomes with an aqueous core surrounded by a polymer bilayer. The difference 
between polymersomes and nanocapsules is depicted in Figure 0.9. 
Nanocapsules have found utility in the encapsulation and delivery of hydrophobic 
drugs and proteins. Commonly used polymers include PLA, PLGA, and PCL in addition 
to poly(ethylene glycol) PEG. The Rotello group has developed a system using 
nanoparticles to stabilize nanocapsules for the delivery of biologics into cells.68,150,151 The 
synthesis strategy can entrap a variety of cargos including proteins. Caspase-3 and Cas9 
have been delivered in tandem with AuNPs using the nanoparticle stabilized emulsion.69,150  
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Polymersomes are analogous to liposomes with their ability to encapsulate and 
deliver hydrophilic substances but are instead made of block copolymers such as PEG-b-
PBD (polybutadiene) and PEG-b-PEE (polyethylethylene). While both systems are inert, 
neither are biodegradable lending to the creation of PEG-b-PLA and PEG-b-PCL. Another 
study using the triblock PEG-PCL-PDEA (polydimethyl amine) polymersomes showed 
delivery of FITC labeled lysozyme, cyt-c, OVA, and IgG into HeLa and Raw cells.152  
In terms of degradable carriers, anisamide decorated pH sensitive polymersomes 
showed efficient loading and delivery of apoptotic granzyme B into H460 lung cells.153 
The reducing environment within the cell dissembled the polymersomes allowing release 
of granzyme B into the cytosol. Cytosolic delivery induced apoptosis via delivery of 
granzyme B when the surface of the polymersomes were functionalized with high levels 
of anisamide on the surface. Nanocapsules and polymersomes provide a ripe area of 
research for protein delivery because of their ability to encapsulate a variety of cargos and 
to be environmentally responsive.  
1.6.6 Polyplexes 
Polyplexes have been traditionally labeled as a complex between polymers and 
DNA, though similar strategies are being applied to proteins.9,154,155 Direct covalent 
attachment with polymers such as PEG has been used to improve stability and reduce the 
surface charge of proteins. Polymer attachment is easily achieved through well-established 
bioconjugation methods.149 One of the most commonly used polymers is 
polyethyleneimine (PEI) which has been conjugated to the surface of various proteins to 
impart positive charge and enhance membrane permeability.156–158 Murata et. al. 
functionalized denatured human tumor suppressor p53 with PEI using a reducible disulfide 
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bond to deliver the protein into Saos-2 cells. Reduction of the reversibly cationized 
complex in the cytosol allowed the p53 to refold into tetramers resulting in nuclear 
localization and induction of p53 target genes eventually leading to apoptosis.125 The 
system was extended to allow delivery of functional anti-S100C antibodies into HFL-1 
cells which could be seen in fluorescence images (Figure 0.10) as long filamentous 
structures as they bound to the S100C proteins on the actin filaments.156 
 
Figure 0.10. Confocal microscopy of distribution of FITC-labeled anti-S100C 
antibodies localized with actin (A) after delivery with the PEI cationized protein G 
into HFL-1 cells (scale bar 50 µm). Delivery of a non-specific protein with PEI-protein 
G resulted in unpatterned delivery (B). Lower images are differential interference 
contrast images corresponding to the upper panels. Arrowheads indicate filamentous 
structures. Image adapted from Kitazoe et. al.156 
In another case, cytosolic delivery of MoAb 64.1 was demonstrated in Jurkat T 
cells using polypropylacrylic acid.159 The antibody was conjugated to streptavidin which 
readily complexed with the biotinylated polymer allowing for release into the cytosol as 
determined by quantitative western blot.  
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1.6.7 Insight 
Polymer nanocarrier systems are one of the fastest growing transduction methods 
due to facile synthesis and high uptake of detectable bioactive cargo. Synthetic carriers tout 
enhanced cargo stability in addition to permeability, though many studies do not look at 
the long term effects of the synthetic systems within cells. Additionally, there has been 
very few systematic comparisons between polymer systems probing how formulation and 
preparation effects protein delievery.160 Expansion into structure activity relationships, as 
well as understanding how the protein cargos interact with their carriers is critical to 
improving polymer design for improved uptake and protein function.  
 
1.7 Perspective 
The intracellular delivery of functional proteins is an important task as it opens the 
doors to understanding and manipulating intracellular pathways with low toxicity and 
minimal interruption in normal cellular processes. Effective and safe delivery systems 
facilitate progress in multiple fields from cell bases therapies to molecular biology. Current 
demand for these delivery vehicles exceeds supply, especially in fields that are interested 
in treatment of primary and patient derived cells such as immune cells, neurons, and stem 
cells. 
One major challenge that the field of protein delivery currently faces is the lack of 
standard experimental conditions to compare across all protein delivery methods. Many 
publications (not included in this review) only deliver fluorescently labeled cargos, which 
have no other detectable bioactivity, and rarely do the authors follow up with proteins that 
do show a bioactive readout. Model proteins that exhibit function either in the cytosol or 
nucleus easily demonstrate endosomal escape and the stabilizing capacities of the carriers. 
 34  
Additionally, researchers have tendencies and preferences for certain cell lines which limits 
the diversity of cells studied and makes comparisons between methods even more 
challenging. Many of the reported cell lines, like HeLas, are known to be relatively easy to 
transfect and transduce, providing little barrier and less proof of concept. Here, the authors 
would like to encourage the field to begin to choose proteins that have a functional readout 
within the cells they are delivered into, and to deliver into cell lines or primary cells that 
have practical application such as immune cells or neurons.  
An important, yet unanswered question that protein delivery faces is how much 
protein is required to have a biological response. Without quantification, or understanding 
of how concentration effects an intracellular pathway, it remains elusive whether one 
protein or many are needed to register a biological readout. Therefore, higher number of 
delivered proteins is not necessarily as important for functional protein delivery. Direct 
structure activity relationships would help elucidate this problem, furthering the 
development of more effective protein delivery.  
The future of protein delivery is dependent on interdisciplinary research to facilitate 
the interface of biology and technology. Advances in delivering proteins across the 
membrane will lead to new challenges. Solving these next generation problems may hinge 
on our ability to understand current delivery mechanisms and implement analytical 
approaches necessary to characterize cellular response. Despite the barriers that remain, 
next generation technologies will translate beyond academic endeavors into personalized 
diagnostics and therapeutics. 
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1.8 Thesis Overview 
The aim of the following thesis was to characterize, optimize, and utilize PTDMs 
for functional protein delivery. The PTDMs reported here provide a well-controlled 
platform to vary molecular composition for structure activity relationship studies to further 
our understanding of PTDs, their non-covalent association with cargo, and their cellular 
internalization pathways. Specifically, several polyoxanorbornene-based synthetic mimics 
were synthesized using ring-opening metathesis polymerization (ROMP) due to its 
relatively precise control over molecular weight and polydispersities. The living nature of 
ROMP allows for the formation of advanced architectures such as block copolymers which 
can be used to investigate the relationship between structure and internalization activity.  
Elucidating the predominant cellular entry mechanism for protein transduction 
domains (PTDs) and their synthetic mimics (PTDMs) is a complicated problem that 
continues to be a significant source of debate in the literature. In Chapter 2, several 
guanidine rich homopolymers, along with an amphiphilic block copolymer were used to 
investigate the relationship between structure and internalization activity in HeLa cells, 
both alone and non-covalently complexed with EGFP by flow cytometry and confocal 
imaging. The findings indicate that while changing the amount of positive charge on our 
PTDMs does not seem to affect the endosomal uptake, the presence of hydrophobicity 
appears to be a critical factor for the polymers to enter cells either alone, or with associated 
cargo. 
In Chapter 3, a series of polyoxanorbornene-based synthetic mimics, inspired by 
PTDs, with varying cationic and hydrophobic densities, and the nature of the hydrophobic 
chain and degree of polymerizations were investigated in vitro to determine their ability to 
non-covalently transport enhanced green fluorescent protein into HeLa cells, Jurkat T cells, 
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and hTERT mesenchymal stem cells. Polymers with high charge density lead to efficient 
protein delivery. Similarly, the polymers with the highest hydrophobic content and density 
proved to be the most efficient at internalization. The observed improvements with 
increased hydrophobic length and content were consistent across all three cell types, 
suggesting that these architectural relationships are not cell type specific. These results 
provide important design parameters for intracellular delivery of proteins and produced a 
candidate polymer for further investigation. 
Delivery of a model protein, GFP, into several human cell types using the lead 
PTDM compared with four commercially available counterparts is explored in Chapter 4. 
This comparison reveals that while many of the protein delivery vehicles within the class 
of amphiphilic polymers are able to deliver into cells in serum free conditions, their 
delivery is severely hampered in the presence of serum. In contrast, the PTDM reported 
here is capable of high protein delivery into all tested cell types within 4 hours in the 
presence of complete media. 
Lastly, to show functional protein delivery, in Chapter 5 we investigated the ability 
of these PTDMs to deliver a peptide into whole blood and subsequent stimulation of a 
directed immune response toward the specific peptide sequence. We have detected peptide 
delivery to over 90% of CD14+ monocytes in less than 15 minutes with nominal cytokine 
response and high cell viability. The co-delivery of an agonist to promote a specific 
immune response against the peptide in vitro allowed us to modulate monocyte 
differentiation and presentation of the specific peptide in association with MHC class I 
molecules. The ability to have a specific response with the cargo of interest verifies 
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cytosolic delivery using the PTDMs and provides valuable insight into their use to affect 
immune cells. 
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CHAPTER 2 
RELATING STRUCTURE AND INTERNALIZATION FOR ROMP-BASED 
PROTEIN MIMICS 
2.1. Introduction 
Over the past decade, intracellular targeting has become an emerging area of 
research in drug delivery, diagnostics, and chemical biology. However, cell membranes are 
impermeable to most macromolecules and small molecules. One exception seems to be a 
class of cell-penetrating peptides (CPPs) known as protein transduction domains (PTDs) 
and their synthetic mimics (PTDMs). Intracellular delivery using PTDs remains a 
promising method for introducing exogenous macromolecules into cells.161,162 
The Tat (transactivator of transcription) protein of the human immunodeficiency 
virus type 1 (HIV-1), discovered in 1988, was the first identified PTD.163,164 Later, it was 
determined that an eleven amino acid residue sequence (YGRKKRRQRRR), rich in basic 
amino acids, was required for translocation of Tat through the plasma membrane.165 In the 
last two decades, over 100 CPP sequences have been published and this number continues 
to expand as more is learned about these molecules.166 These CPPs are usually small, 
cationic peptides, some of which contain a hydrophobic component. Their main feature is 
their ability to cross cell membranes either on their own or conjugated to a range of 
biomolecules, such as peptides, proteins, liposomes, and nanoparticles. This is possible at 
micro-molar concentrations without causing significant membrane damage.58 Synthetic 
CPPs deviate from naturally occurring protein sequences and are either designed to mimic 
their structures and compositions or to produce amphipathic a-helical structures. Examples 
are the model amphipathic peptide (MAP) and oligoarginine sequences, such as R8. These 
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synthetic CPPs have also been covalently attached to various macromolecules and their 
internalization has been studied.167,168  
Intracellular delivery of large molecules, including macromolecules and liposomes, 
often involves the uptake of PTD(M) complexes by endocytosis.169 Arginine-rich PTDMs 
have been proposed to induce macropinocytosis, which in turn leads to accelerated 
internalization of cell surface adsorbed PTDMs and PTDM-cargo complexes.170–172 Since 
macropinocytosis is considered a non-specific fluid phase endocytosis pathway, its 
induction should facilitate indiscriminate uptake.173 The endosomal route usually finishes 
with the acidic and proteolytic degradation of the lysosomal content, thus preventing the 
delivered cargo from reaching its cytosolic targets.174 The release of biologically active 
cargo from endosomes is a necessary step and is a major limitation for this type of uptake.58 
A second mode of uptake is direct translocation, an energy-independent penetration 
pathway in which a transient destabilization occurs in the membrane, followed by the rapid 
intracellular localization of the peptide.175–177 For drug delivery purposes, it is preferred 
that molecules enter cells by direct translocation, as this pathway does not incur endosomal 
entrapment. Changes in hydrophobicity have been implicated as the driving factor for 
arginine-rich molecules to cross cell membranes through direct translocation.178 
Additionally, cell surface concentrations of arginine-rich PTDMs may also play a role in 
peptide entry into cells.179 Some peptides exceeding a threshold concentration have been 
observed to directly penetrate the membrane, while at lower concentrations uptake is 
primarily by endocytosis.177,180,181  
A change in membrane curvature is required for both endocytosis and direct 
penetration, which can be facilitated by CPP–membrane interactions.182 Decoupling 
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endocytosis from direct penetration remains largely unsolved. The use of endocytosis 
inhibitors may alter other cellular processes, making deconvolution of the treatments 
difficult.183 Cooling cells to 4 ˚C provides another challenge in that cooler temperatures 
affect the membrane fluidity making it more rigid and therefore more permeable to larger 
molecules.184  
While many CPPs and their mimics show high membrane permeability and 
efficient cargo delivery, the mechanisms by which PTDMs and PTDM-cargo complexes 
traverse cell membranes are not completely understood and are highly debated in the 
literature.183 The methods by which arginine-rich PTDs are internalized depend on the 
physiochemical properties of the PTDs, the cargo molecules, and cell type, as well as a 
variety of other parameters. Therefore, it is not surprising that the predominant 
internalization mechanism may deviate depending on the attached cargo. Understanding 
this cellular uptake mechanism of CPPs under physiological conditions is important for the 
development of appropriate strategies for therapeutic applications both in vitro and in vivo. 
Since several routes may exist simultaneously, it is important to correlate the uptake 
pathway with the biological response associated with a specific cargo e.g. if the target of 
the cargo is cytosolic or endosomal. These parameters will enable the design of materials 
to target specific routes of internalization. 
Creating polymeric scaffolds with CPP-like internalization and cargo delivery 
properties has recently emerged as a new research direction.114–116 Polymers allow for the 
use of different, easily tailored chemistries and architectures for investigating structure 
activity relationships, while tuning for efficient cargo delivery. Using ring-opening 
metathesis polymerization (ROMP), which is functional group tolerant, well-controlled, 
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and versatile, a highly efficient set of synthetic PTDMs has been developed.114,115,185–190 
These designs, based on polyarginine, are guanidinium-rich and allow for non-covalent 
internalization of various biological cargos.187,188,191 The ability to easily include diverse 
functional groups allows us to probe architecture, molecular composition, and molecular 
weight in a controlled manner, mimicking peptide synthesis.114,191  
Polymeric mimics offer a controlled way to explore the effects of structure and 
macromolecular composition on internalization efficiency. Using R8 as inspiration and a 
benchmark, a set of four homopolymers and one block copolymer (Figure 0.1) were chosen 
to investigate the impact of polymer structure and backbone on internalization efficiency 
in HeLa cells. 
 
Figure 0.1. Polymers of interest: R8 inspired the design of dG5 (n=5), dG10 (n=10), 
MeG10, PGON20, and MePh10-b-dG5. 
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Determining the parameters that dictate the predominant method of internalization 
is crucial to the understanding and optimization of CPPs and their mimics. In this work, 
we use the delivery of cargo by synthetic PTDMs as a handle for elucidating the 
intracellular pathways through which these molecules enter. More specifically, HeLa cells 
were treated with the chosen PTDMs, either with a FITC label or associated with 
fluorescent protein, allowing for confocal laser scanning microscopy (CLSM) and flow 
cytometry (FCM) analysis. Imaging explicates the predominant mode of uptake as 
endosomal uptake and allows us to address some of the more difficult questions regarding 
polymer-cell interactions, while flow cytometry generates quantitative results (on a much 
larger number of cells) that can be used to verify trends seen with imaging. From these 
results, we determined that concentration and polymer architecture have little effect on the 
mode of translocation into the cell, but rather play a more important role in how much 
cargo they are able to deliver.  
2.2. Materials and Methods 
2.2.1. Materials 
Chemicals were obtained as reagent grade from Aldrich, Fluka, or Acros and used 
as received. 3rd generation Grubbs catalyst (Dichloro-di(3-bromopyridino)-N,N’-
Dimesitylenoimidazolino-Ru=CHPh; G3) was synthesized as described previously by 
Grubbs et al. (1). The ACS reagent grade solvents, ethyl acetate, tetrahydrofuran (THF), 
N,N-dimethylformamide (DMF), and pentane, were purchased from Fisher Scientific and 
used as received. Dichloromethane (DCM) (ACS reagent grade, Fisher Scientific) was 
distilled from CaH2 under nitrogen. Deuterated solvents for NMR were purchased from 
Cambridge Isotope Laboratories. Spectra/Por® Biotech cellulose ester dialysis membranes 
 43  
with the molecular weight cut off of 100-500 were purchased from Spectrum Medical 
Industries. Media and supplements for cell culture were purchased from Lonza. 
 
2.2.2. Instrumentation 
1H spectra were recorded at 300 MHz, using a Bruker DPX-300 NMR 
spectrometer. Chemical shifts (δ) are reported in ppm and coupling constants (J) in Hz. 
The abbreviations for splitting patterns are: s, singlet; d, doublet; dd, doublet of doublets; 
t, triplet; q, quartet; m, multiplet; br, broad. Gel permeation chromatography was measured 
on an Agilent 1260 series GPC setup with a PL Gel 5 µm guard column, two 5 µm 
analytical Mixed-C columns, and a 5 µm analytical Mixed-D column (Agilent), incubated 
at 40 °C, with RI detector. THF was used as the eluent at a flow rate of 1.0 mL/min. 
Polystyrene standards were used for the calibration and toluene was used as flow marker. 
Flow cytometry was performed on an LSRII flow cytometer and analyzed using the 
acquisition software FACSDiva™ (BD®). Analysis of flow cytometry data was performed 
using FlowJo™ (Tree Star®) software. Images were taken using a FV1000 Olympus® 
IX81 confocal laser scanning microscope (CLSM) at both 40 and 60X. 
2.2.3. PTDM Synthesis 
2.2.3.1. Monomer Synthesis 
Monomers and PTDMs were synthesized according to established literature 
procedures.185,187,189 The diester monomers were synthesized using the procedure 
introduced by Lienkamp et al.192 In general, the Diels-Alder adduct 1 was obtained by the 
reaction of maleic anhydride with furan in toluene. 
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1 was dissolved in the minimum amount of dry DCM together with 2 eq. of 1,2-Di-
Boc-2-ethyl guanidine, and 10 mol% 4-dimethylaminopyridine (DMAP). The temperature 
was lowered to 0°C with an ice bath and 1 eq. of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) was added, then stirred over night at room 
temperature. After completion of the reaction, the solution was concentrated and the 
product was purified via column chromatography with silica gel using DCM/ethyl acetate 
(8:2) as eluent. Vacuum evaporation of the solvent yielded the pure product with a yield of 
~80%.  
 
3 (dG): 1H NMR (300 MHz, CD3CN): δ 11.54 (s, 2H), 8.35 (s, 2H), 6.44 (s, 2H), 5.17 (s, 
2H), 4.33 – 3.97 (m, 4H), 3.72 – 3.41 (m, 4H), 2.82 (s, 2H), 1.48 (s, 9H), 1.42 (s, 9H); 13C 
NMR (75 MHz, CD3CN): δ 172.43, 164.51, 157.35, 153.72, 137.56, 84.05, 81.41, 79.50, 
63.72, 47.49, 40.21, 28.38, 28.09; HR-MS (FAB) m/z [M+H]+: 755.3827 (calc.), 755.3824 
(found). 
Compound 1, 1.5 equivalents of methanol, and 10 mol% DMAP were dissolved in 
dry DCM and the reaction was stirred for 3 days at room temperature. Solvent was 
evaporated and the product was crystalized in a 1:1 mixture of chloroform:hexanes with a 
yield of ~60%.The product was dissolved in dry DCM along with 1.5 equivalents of 1,2-
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Di-Boc-2-ethyl guanidine, and 10 mol% DMAP and the solution was cooled to 0˚C. 1 
equivalent of EDC was added and the reaction was stirred overnight at room temperature. 
The product was washed with brine, evaporated down, and purified using column 
chromatography with silica gel 9:1 DCM:ethyl acetate. The yield was ~70%.  
4 (MeG): 1H NMR (300 MHz, CD3CN): δ 11.50 (s, 1H), 8.55 (s, 1H), 6.46 (s, 2H), 5.3 (d, 
2H), 4.25 (m, 2H), 3.72(m, 5H), 2.84 (s, 2H), 1.49 (s, 18H). 13C NMR (75 MHz, CD3CN): 
δ 171.7, 171.5, 163.4, 156.3, 153.1, 136.6, 83.2, 80.7, 80.6, 79.4, 63.5, 52.4, 47.1, 46.4, 
39.4, 28.3, 28.1; HR-MS (FAB) m/z [M+H]+: 483.22 (calc.), 484.23 (found). 
Compound 1, 1.5 equivalents of benzyl alcohol, and 10 mol% DMAP were 
dissolved in dry DCM and the reaction was stirred for 3 days at room temperature. The 
product was precipitated out of DCM and was filtered and vacuum evaporated to yield the 
pure product with a yield of ~70%. The product was dissolved in 1:1 mixture of DCM:THF 
along with 2 equivalents of methanol and 10% DMAP and the solution was cooled down 
to 0˚C in an ice bath. 1 equivalent of EDC was added and the solution was stirred over 
night at room temperature. Solvent was evaporated off and the reaction mixture was 
dissolved in minimal DCM. Purification of monomer MePh was performed via column 
chromatography with silica gel using DCM:ethyl acetate (8:2) as eluent. Vacuum 
evaporation of the solvent yielded the pure product with a yield of ~80%. 
(MePh): 1H NMR (300 MHz, CD3CN): δ 7.34 (d, J = 3.0 Hz, 10H), 6.44 (s, 2H), 5.16 (s, 
2H), 4.97 (dd, J = 45.5, 12.4 Hz, 4H), 2.87 (s, 2H); 13C NMR (75 MHz, CD3CN): δ 172.37, 
137.52, 137.03, 129.41, 129.14, 129.06, 81.30, 67.26, 47.58; HR-MS (FAB) m/z [M+H]+: 
365.1389 (calc.), 365.1398 (found). 
 46  
The imide monomer was synthesized using a procedure previously developed by 
Gabriel et al. 2 In general, the Diels-alder adduct was obtained by the reaction of maleimide 
with furan in ethyl acetate at 90˚C for 3 hours. The product, 1,2-Di-Boc-2-ethyl guanidine, 
and triphenylphosphine were dissolved in THF and cooled to 0˚C. 1 equivalent of 
diisopropyl azodicarboxylate (DIAD) was added dropwise and reaction was stirred for 24 
hours at room temperature. Solvent was removed by evaporation and recrystallized in 
methanol twice to yield 40% of the GON monomer.  
5 (GON): 1H NMR (300 MHz, CD3CN): δ 11.44 (s, 1H), 8.35 (t, J = 6.0 Hz, 1H), 6.56 (s, 
2H), 5.10 (s, 2H), 3.52 (m, 2H), 3.43 (m, 2H), 2.85 (s, 2H), 1.47 (s, 9H), 1.36 (s, 9H); 13C 
NMR (75 MHz, CD3CN): δ 176.3, 156.6, 153.0, 136.5, 83.3, 80.9, 47.6, 39.0, 38.4, 28.3, 
28.1. 
2.2.3.2. Activated Ester Synthesis 
Activated ester was synthesized according to the procedure introduced by Madkour 
et al. Briefly, compound B was synthesized as described in the literature. 3 Compound A, 
pentafluorophenol, and DMAP were dissolved in 50 mL dry DCM under nitrogen. The 
resulting solution was then cooled to 0˚C, and EDC was added to the mixture in portions. 
The reaction mixture was then allowed to warm to room temperature and stirred for another 
12 hours. The mixture was then washed with 10% KHSO4 solution, saturated NaHCO3 
solution, and brine. The resulting DCM solution was dried using anhydrous Na2SO4, 
filtered, and the solvent was evaporated. The resulting residue was purified by filtration 
through a neutral alumina plug using DCM as the eluent.  
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1H-NMR (300 MHz, CDCl3): δ 5.77 (m, 2H), 4.75 (d, J = 5.6 Hz, 4H), 3.05 (t, J = 6.2 Hz, 
4 H), 2.95 (t, J = 6.2 Hz, 4H); 13C-NMR (75 MHz, CDCl3): δ 171.1 (C=O-O allylic), 168.4 
(C=O-O-C6F5), 142.9, 141.7, 139.5,137.8 & 136.1 (m, F5C6), (CH2-C=C), 28.7 & 28.3 
(CH2-CH2). 
2.2.3.3. Polymer Synthesis 
Example of reaction conditions for homopolymer synthesis: Monomer (MeG or 
dG) and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged with 
nitrogen and subjected to three freeze-pump-thaw cycles. The monomer solution was 
added into the catalyst solution via syringe all at once. The brown solution was stirred for 
2 hours (30 minutes for the PGON20) at room temperature. The reaction was terminated 
with 1 mL of ethyl vinyl ether and stirred for 30 minutes. DCM was evaporated and the 
product dissolved in minimal DCM to be loaded on a short silica gel column (7 cm length, 
3 cm diameter). The unreacted end-group and any side products were washed from the 
column with DCM, while polymer remained on the column and was recovered with ethyl 
acetate. Ethyl acetate was evaporated to yield the pure product.  
 
MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88 
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br), 
3.65 (5H, br), 3.17 (2H, br), 1.49 (18H, s). 
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dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93 
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br), 
3.59 (4H, br), 3.21 (2H, br), 1.53 (18H, s), 1.44 (18H, s). 
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93 
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br), 
3.58 (4H, br), 3.19 (2H, br), 1.52 (18H, s), 1.44 (18H, s). 
PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br), 
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H, 
br), 3.33 (2H, br), 2.09 (2H, br), 1.38 (18H, s). 
 
Reaction conditions for block copolymer synthesis: Monomer dG, monomer 
MePh, and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged 
with nitrogen, and subjected to three freeze-pump-thaw cycles. Monomer dG solution was 
added into the catalyst solution via syringe all at one time. The brown solution was stirred 
for 30 minutes at room temperature before monomer MePh was introduced. After stirring 
for an additional 2 hours, the reaction was terminated with 1 mL of ethyl vinyl ether and 
stirred for 30 minutes. DCM was evaporated and the product was dissolved in minimal 
DCM and loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted 
end-group and any side products were washed from the column with DCM, while polymer 
remained on the column and was recovered with ethyl acetate. Ethyl acetate was 
evaporated to yield the pure product.  
 
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H, 
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H 
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total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 1.46 (18H, 
s), 1.41 (18H, s).  
 
Polymers were synthesized in a similar manner to that listed above but terminated 
with 20 mole equivalents activated ester (compound B) dissolved in a minimal amount of 
DCM and stirred overnight. DCM was evaporated and the product dissolved in minimal 
DCM to be loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted 
end-group and any side products were washed from the column with DCM, while polymer 
remained on the column and was recovered with ethyl acetate. Ethyl acetate was 
evaporated to yield the pure product.  
 
MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88 
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br), 
3.65 (5H, br), 3.17 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.49 (18H, s). 
dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93 
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br), 
3.59 (4H, br), 3.21 (2H, br), 3.02 (cis) and 2.77 (trans) (0.8H total, br), 1.53 (18H, s), 1.44 
(18H, s). 
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93 
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br), 
3.58 (4H, br), 3.19 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.52 (18H, s), 1.44 
(18H, s). 
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PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br), 
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H, 
br), 3.33 (2H, br), 3.02 (cis) and 2.79 (trans) (0.2H total, br), 2.09 (2H, br), 1.38 (18H, s). 
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H, 
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H 
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 3.01 (cis) 
and 2.77 (trans) (0.3H total, br), 1.46 (18H, s), 1.41 (18H, s).  
100 mg end-functionalized polymer was dissolved in 1 mL amine-free DMF. 2 
mole equivalents of fluorescein-5-thiosemicarbazide were added. The reaction was 
allowed to stir at room temperature for three days. The solvent was evaporated, and the 
reaction product was purified by column chromatography using ethyl acetate.  
 
MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88 
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br), 
3.65 (5H, br), 3.17 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.49 (18H, s). 
dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93 
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br), 
3.59 (4H, br), 3.21 (2H, br), 3.02 (cis) and 2.77 (trans) (0.8H total, br), 1.53 (18H, s), 1.44 
(18H, s). 
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93 
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br), 
3.58 (4H, br), 3.19 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.52 (18H, s), 1.44 
(18H, s). 
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PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br), 
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H, 
br), 3.33 (2H, br), 3.02 (cis) and 2.79 (trans) (0.2H total, br), 2.09 (2H, br), 1.38 (18H, s). 
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H, 
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H 
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 3.01 (cis) 
and 2.77 (trans) (0.3H total, br), 1.46 (18H, s), 1.41 (18H, s).  
2.2.4. Deprotection 
The polymers were dissolved in 2 mL DCM and 2 mL trifluoroacetic acid (TFA) 
for deprotection. After stirring overnight, the excess acid was removed by azeotropic 
distillation with methanol. After complete evaporation of the acid, samples were dissolved 
in water/methanol mixture and dialyzed against RO water until the conductivity of water 
was ~0.1µS. The deprotected copolymer was recovered by lyophilization. Final 
deprotected polymer was stored at -20 ºC. 
2.2.5. Internalization of FITC-Labeled Polymers 
HeLa cells were seeded at 1x104 cells/ 2 mL of a-MEM with 10% FBS on 35 mm 
glass bottom plates 48 hours prior to treatment and cultured at 37˚C and 5% CO2. FITC-
PTDMs were diluted 1:10 in PBS and then to a final concentration of 5, 10, and 20 µM in 
a-MEM with 10% FBS. Cells were washed with warm, fresh, complete media and 200 µL 
of PTDM solution was applied on top of the glass bottom. Cells were incubated for one 
hour and then washed three times with cold media to remove excess PTDM and to slow 
cellular function. Cells were covered in 1 mL of cold media and imaged at 60X with 
confocal laser scanning microscope (CLSM). 
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To investigate co-localization with lysosomes, cells were treated with 5 µM FITC-
PTDM and 20 nM lysotracker red for 1 hour. Samples were analyzed in a similar manner 
to the internalization experiments using both red and green lasers on the CLSM. 
Correlation between the location of the lysotracker and the FITC-PTDM was determined 
by Pearson’s co-localization coefficient (PCC) using Autoquant® software. 
2.2.6. EGFP Delivery 
HeLa cells were seeded at 1x106 cells/ 2 mL of a-MEM with 10% FBS on 35 mm 
glass bottom plates and 1x105 cells/ 1 mL on 12-well plates 48 hours prior to treatment and 
cultured at 37˚C and 5% CO2. Polymer was complexed with 2 µg of EGFP using previously 
reported methods at a ratio of 20:1 PTDM to protein (unpublished). Cells were treated for 
four hours with the polymer/protein complexes in a total volume of 1 mL a-MEM with 
10% FBS. Before imaging, cells were washed three times with cold media and covered in 
1 mL fresh, cold a-MEM with 10% FBS. Cells were imaged using CLSM at 60X. To 
prepare for flow cytometry (FCM), the cells were lifted using trypsin and washed three 
times with a 20 U/mL heparin solution before being suspended in PBS with 0.2 wt% FBS. 
To determine if the 30 minute incubation period was required for optimal uptake, 
cells were treated with PTDMs not incubated with protein at the same concentration. 
PTDMs and protein were diluted as stated above and added drop-wise without mixing into 
the media. Uptake was analyzed by flow cytometry to determine the percentage of cells 
that internalized the polymer, as well as the median fluorescence intensity (MFI) of the 
cells. Cell viability was determined using 7-aminoactinomycin D (7-AAD) staining. 
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2.3. Results and Discussion 
2.3.1. Polymer Design and Synthesis 
In this study, PTDMs were designed to resemble R8 (Figure 0.1), with MeG10 
containing one guanidinium group per repeat unit, yielding about 10 positive charges per 
polymer. The diguanidine (dG) series (dG5 and dG10) was designed to create a higher 
density of guanidinium groups to better mimic the distribution of charge along the peptide 
backbone. dG5, with about 10 positive charges, correlates to R8 in that it has approximately 
the same number of guanidinium groups, but only half the number of repeat units, while 
dG10 has approximately the same number of repeat units as R8, but has twice as many 
guanidinium moieties, or about 20 positive charges. A second ROMP backbone, the imide-
based poly-guanidinium oxanorbornene (PGON), was added to the series because of its 
high membrane activity with lipid vesicles.189 Since PGON20 only contains one 
guanidinium group per repeat unit, a length of 20 was chosen for comparison to dG10, 
resulting in about 20 positive charges along the length of the polymer. Lastly, a block 
copolymer with 10 hydrophobic and 5 diguanidinium monomers (MePh10-b-dG5) was 
included because of its efficient non-covalent protein delivery into Jurkat T Cells 
(unpublished), predominantly due to the added hydrophobicity that has been shown to be 
required for efficient protein delivery. Added hydrophobicity, which has been predicted to 
increase saddle splay curvature, combined with lipid head-group coordination by 
guanidinium groups, promotes membrane permeation.182 These polymers were all 
synthesized with and without covalently attached FITC labels.  
2.3.2. Internalization of FITC-Labeled Polymers 
HeLa cells were treated with FITC-PTDMs for 1 hour and imaged using a CLSM, 
as shown in Figure 0.2A, and also analyzed using flow cytometry (Figure 0.2B and C). 
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Images revealed that dG5 and MeG10 exhibited low cell entry. MeG10 appeared to 
aggregate extensively and was dropped from further studies. This aggregation could be due 
to the overall charge density being too low, with one charge per monomer, allowing the 
PTDMs to have a greater self-affinity than for the solution or cell membranes. Both 
homopolymers with 20 guanidinium units (PGON20 and dG10) demonstrated efficient 
internalization, particularly PGON20. This is unsurprising, as previous reports have shown 
that it is highly membrane active in biophysical assays compared to other homopolymers 
produced in this group.185 The block copolymer PTDM also showed punctate 
internalization throughout the cell with high efficiency for all imaged cells.  
The median fluorescence intensities (MFIs), shown in Figure 0.2B, corroborate the 
confocal images. An artificially high MFI is expected from MeG10, since large aggregates 
were seen in and on cells in the confocal images. dG10 and PGON20 showed high 
membrane activity (see Figure 0.2) and consequently result in a 3 to 4 fold higher MFI than 
MePh10-b-dG5. We speculate that efficient internalization with the dye requires a 
combination of a critical hydrophobic component and charge content that is not met with 
dG5. Along this line of thought, the internalization of PGON20 could be attributed to its 
increased length. Although MePh10-b-dG5 resulted in a low MFI, the punctate fluorescence 
was prevalent in all imaged cells, and more than 95% of the cell population was fluorescent.  
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Figure 0.2. Internalization of FITC-labeled PTDMs into HeLa cells. Cells were 
treated with 5 µM PTDM for 1 hour and imaged with a CLSM (A) and assessed for 
fluorescence internalization using a flow cytometer for both MFI (B) and a positive 
shift in intensity from the blank (grey) in FCM histograms (C). Polymer colors in (B) 
correspond to their respective shifts in (C). 
While punctate fluorescence is easily visible, the location and type of endosomal 
compartments was still in question. To determine if the PTDMs were trapped in endosomes 
and if those endosomes were bound for degradation, co-localization with lysotracker was 
investigated.  
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2.3.3. Co-localization with Lysosomes 
To compare the location of internalized PTDMs with late endosomal 
compartments, cells were treated with lysotracker red during the treatment with FITC-
PTDMs (Figure 0.3). FITC-PTDMs (green) trapped in late endosomes should co-localize 
with the lysotracker red, indicated by yellow. 
 
Figure 0.3. Internalization of FITC-PTDMs (green) in the presence of lysotracker 
(red) in HeLa cells. Cells were treated with 5 µM FITC-labeled polymer and 
lysotracker red for one hour and imaged using a CLSM.  
While the diester homopolymers (dG5 and dG10) proved less successful at 
internalization, R8, PGON20, and MePh10-b-dG5 showed robust internalization in punctate 
structures. Some of the MePh10-b-dG5 appears to overlap with the lysotracker red, 
suggesting that endosomal entrapment is involved in internalization. The enlargement of 
MePh10-b-dG5 with lysotracker red is overlapped (yellow), but mutual exclusion of the 
polymer (green) from the late endosomes (red) also exists. The Pearson’s Correlation 
Coefficient (PCC) for the homopolymer PTDMs and R8 was approximately 0.3 for all 
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samples, suggesting little to no correlation between the lysotracker and the polymer, while 
MePh10-b-dG5 had a PCC of 0.8, suggesting high co-localization with the late endosomes. 
In other words, the hydrophobic PTDM was able to internalize in late endosomes but was 
not exclusively located there. This suggests that while some PTDM is permanently trapped 
in endosomes, it is not necessarily all destined for degradation. Additionally, escape from 
endosomal compartments cannot be dismissed. Longer time periods of this study with a 
more photo stable dye would allow for further investigation on the kinetics of our polymers 
within cells but was not the focus of this study.  
2.3.4. Concentration Dependence 
Since the mechanism of uptake can be dependent on the experimental conditions, 
an increase in concentration of MePh10-b-dG5 and R8 was used to investigate the effect of 
concentration on the predominant mode of internalization. Increasing the concentration 
appeared to increase the amount of R8 and MePh10-b-dG5 that entered the cell, although 
with increasing cytotoxicity (Figure 0.4A). Confocal images showed that at higher 
concentrations of both PTDMs, cells began to bleb and appeared unhealthy. More 
aggregated punctate fluorescence suggests compromise of the cellular membrane. The 
increase in fluorescence intensity and decrease in viability (using 7-AAD) with increasing 
concentration was quantified using flow cytometry. As shown in Figure 0.4, R8 decreases 
to approximately 20% viability, while MePh10-b-dG5 showed lower induced apoptosis 
even at higher concentrations of PTDMs despite considerable blebbing apparent in the 
CLSM images. There was no change in mechanism observed, as fluorescence remained 
punctate in all images, even after four hours. Although persistent punctate structures would 
suggest the inability of the PTDMs to escape endosomes over short periods of time, it is 
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difficult to exclude some PTDM endosomal escape since these fewer dispersed molecules 
would appear much dimmer by CLSM analysis.  
 
Figure 0.4. Effects of concentration on FITC labeled polymer internalization. 
Concentration dependence for MePh10-b-dG5 and R8 labeled with FITC at 5, 10, and 
20 µM (A). HeLa cells were treated with 1 hour with PTDMs and imaged with a 
CLSM and assessed for MFI (B) and viability (C) using flow cytometry.  
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2.3.5. EGFP Delivery 
Polymers were tested for transduction efficiency with enhanced green fluorescent 
protein (EGFP) as an indication of internal cell location and delivery efficiency. The 
PTDMs and protein were incubated for 30 minutes to allow for the formation of non-
covalent complexes and then applied drop-wise to HeLa cells. At four hours, all 
homopolymer PTDMs and R8 proved to be ineffective at delivering protein into the cell, 
showing limited uptake in both the microscope images and FCM data (Figure 0.5). The 
block copolymer showed significantly higher internalization, but was still punctate, 
suggesting entrapment in endosomes within the observed time periods. None of the PTDMs 
or R8 showed any cytotoxic effects compared to the untreated sample, as determined by 
7AAD during flow analysis. While the lack of delivery with the diester homopolymer 
PTDMs was unsurprising because of their poor internalization with the dye, it is interesting 
that PGON20 was unable to facilitate protein internalization. This could be attributed to its 
lack of a defined hydrophobic segment. MePh10-b-dG5 was expected to have high delivery, 
as R8 has been shown to be more effective with a hydrophobic component attached.193 As 
demonstrated here and by others, the hydrophobic domain of the PTDM is important to 
protein internalization.193,194 The block copolymer outperformed all other polymers tested 
at protein delivery yielding an MFI around 20 times higher, as determined by FCM (Figure 
0.5B). This was corroborated with confocal images, which revealed both punctate and 
diffuse fluorescence within the imaged cells (Figure 0.5A). 
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Figure 0.5. EGFP delivery into HeLa cells with unlabeled PTDMs. EGFP was 
complexed with PTDMs for 30 minutes at a molar ratio of 20:1. HeLa cells were 
treated with the complexes for four hours to observe internalization. Cells were 
imaged using a CLSM (A). Internalization efficiency as determined by MFI (B) and 
percent uptake (C) was confirmed using FCM to quantitate the delivery of EGFP. 
Complexed MePh10-b-dG5 with protein was tested in relation to non-complexed 
polymer and protein compared to R8 with and without the protein (D). 
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Additionally, complex formation was tested to determine if the PTDMs merely 
compromise the cell membrane allowing protein into the cytosol, or if they actively 
facilitate transport across the membrane. Cells were treated with MePh10-b-dG5 and R8 
complexed with protein for 30 minutes at room temperature and were compared with cells 
treated directly with the PTDMs followed by protein, which were given no time to form a 
complex. The flow cytometry data, highlighted in Figure 0.5C, showed internalization for 
the cells treated with MePh10-b-dG5 and protein complex, but not for those treated with 
the PTDMs and protein independently. This suggests that MePh10-b-dG5 does not merely 
interact with the membrane to allow indiscriminant uptake of proteins in the cytosol, but 
rather an incubation time is required for the PTDMs to form complexes with the proteins. 
2.4. Conclusion 
While determining the predominant mode of internalization for CPPs remains a 
challenge, using PTDMs to advance the understanding of how structure influences uptake 
activity is critical to improving design parameters for efficient internalization. By 
examining changes in molecular composition in relation to their ability to enter cells when 
complexed with cargo, PTDMs can be enhanced to deliver specific molecules into the cell. 
Here, we performed common methods to assess internalization mechanisms and efficiency 
for guanidinium-containing PTDMs both alone and non-covalently complexed to cargo. 
This provides the first side-by-side studies for this class of PTDMs and R8 with respect to 
cellular internalization. Homopolymer PTDMs proved to be inefficient at entering cells, 
with the exception of PGON20, which was even able to enter cells at a higher capacity than 
the block copolymer PTDM MePh10-b-dG5. Increasing the concentration of the PTDMs 
led to improved internalization but also to higher cytotoxicity, a common observation 
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across PTDMs. None of the homopolymer PTDMs were able to facilitate the delivery of 
EGFP, while MePh10-b-dG5 proved to be exceptionally efficient. Additionally, MePh10-
b-dG5 was the only polymer that also localized with late endosomes, suggesting endosomal 
entrapment for some of the complexes on the time scale used in this study. This finding 
highlights the importance of hydrophobic segments for efficient cargo delivery by PTDMs 
and that these structural changes influence the balance of pathways. These polymers 
remained punctate in the case of internalization for FITC-labeling and protein delivery, 
suggesting that endosomal uptake is the predominant mode of internalization. Findings will 
contribute to future design considerations for intracellular delivery systems and aid in our 
understanding of the modes of internalization for arginine-rich molecular transporters.  
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CHAPTER 3 
INCREASED HYDROPHOBIC BLOCK LENGTH OF PTDMS PROMOTES 
PROTEIN INTERNALIZATION 
3.1. Introduction 
The plasma membrane plays a crucial role in cell survival, acting as a selectively 
penetrable barrier limiting large macromolecules from entering the cytoplasm.195 As the 
field of molecular biology expands, investigation of intracellular processes is often 
hampered by the inability of biomacromolecules, such as proteins and antibodies, to 
efficiently and selectively cross the cell membrane.11 The use of protein transduction 
domains (PTDs), sometimes referred to as cell penetrating peptides (CPPs), to facilitate the 
delivery of large biological cargo can be used to overcome this barrier.10,11,196 PTDs are 
generally short, cationic protein segments with the ability to traverse the phospholipid 
bilayer.197 The first protein discovered with this ability was the HIV-1 TAT protein.163,164 
Subsequent studies found that TAT’s ability to translocate the membrane was largely due 
to the arginine rich domain between residues 48 – 60.165 Guanidinium groups, such as those 
present in polyarginine, have since been shown to be important in facilitating 
translocation.111,176 Through studying TAT and several other naturally occurring PTDs, 
along with their structural derivatives, it became apparent that secondary protein structure 
and peptide based backbones are not essential requirements for efficient cellular uptake, 
but that charge content is critical with guanidine functionality being particularly 
efficient.111,112,165,198–200 Consequently, a large number of highly charged, cationic PTD 
mimics (PTDMs) have been reported.167,201–207  
More recently, addition of a hydrophobic domain has been shown to improve 
membrane transduction activity.208 Examples of this are N-terminal stearylation/acylation 
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of polyarginine,	24 and the use of supramolecular, hydrophobic counter ions,176,209,210 which 
improve both membrane affinity and cellular internalization. Inherently amphiphilic CPPs, 
such as penetratin, have also provided a source of inspiration for chimera mimics like Pep-
1.119,161,211 Additionally, aromaticity has also been shown to play a role in membrane 
interactions and translocation;212–214 oligoarginine activity has been enhanced with the use 
of aromatic counter ions, and with the incorporation of tryptophan or phenylalanine in the 
peptide sequences.215–218  
Given the importance of aromatic amino acids in membrane proteins and their 
unique interactions with the bilayer, it was proposed that aromatic side chains would make 
better activators than other hydrophobic amino acids, given equal relative 
hydrophobicity.111,219,220 We have previously reported the synthesis and preliminary 
investigations of oxanorbornene based guanidinium rich polymer mimics of polyarginine, 
which have shown higher membrane activity compared to their polyarginine 
counterparts.187–189 Aromatic groups have been studied in peptide based CPPs and the role 
of hydrophobicity has been further explored for protein delivery using PTDMs.186,221 More 
specifically, constitutional macromolecular isomers have been used to investigate the 
importance of sequence segregation for protein delivery, instilling the importance of a 
distinct hydrophobic domains.134 Herein, we have designed and characterized eight 
different block-copolymer PTDMs inspired by polyarginine and amphiphilic peptides to 
deliver protein via non covalent complexes into HeLa cells, as well as two hard to transfect 
cell types, Jurkat T cells, and hTERT MSCs, thus providing critical information regarding 
the importance of hydrophobicity in PTDM delivery systems. 
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Polymer mimics offer distinct advantages over peptide derivatives of PTDs in that 
they are functionally and structurally versatile. In our previously reported synthetic 
approach, we achieved well-defined PTDMs with control over the spatial arrangement of 
positive charges and hydrophobic groups. These molecules were obtained using ring-
opening metathesis polymerization (ROMP), a technique well known for its highly 
controlled nature, functional group tolerance, and rapid polymerization times. Here, we 
extend this platform to access a series of block copolymers with precise hydrophobic and 
cationic content and density.134,185–187,191,221,222 Control over monomer hydrophobic content 
also enables deconvolution of side chain hydrophobicity from the hydrophobicity imparted 
by the polymer backbone. Using HPLC to determine the relative hydrophobicity of the 
monomers allows us to relate the hydrophobic content of each polymer, in terms of length, 
with their ability to deliver cargo.  
Attachment of cargo via covalent linkage is often required for efficient use of 
PTDs.128,223,224 The polymers studied here are able to form stable, non-covalent complexes 
with their associated cargos that are then internalized into cells.188 In the context of 
promoting fundamental studies, non-covalent interactions are preferred due to their 
simplicity, delivery efficiency, and minimization of labor.225 To evaluate the ability of 
these protein-containing complexes to enter cells, enhanced green fluorescent protein 
(EGFP) was chosen as a cargo. Flow cytometry was used to determine both the percentage 
of cells that receive the cargo, as well as the extent of uptake in the cells of interest. 
Additionally, cell viability was assessed after treatment, though very little toxicity was seen 
from any of the polymer-protein complexes. 
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In general, we found that a high density of cationic charge with a longer 
hydrophobic block led to higher levels of uptake. While some hydrophobic content 
threshold was required, the overall hydrophobic density seemed to have less of an impact 
than cationic density or length of the hydrophobic block on the ability of the block 
copolymers to efficiently internalize cargo. From this it has been hypothesized that 
increased hydrophobic block length creates a more stable interaction with the cargo protein. 
Similar results were found across all three cell types suggesting that this trend is applicable 
to all ROMP-based oxanorbornene block copolymers. The structure-activity study of these 
PTDMs provides guidance for building polymers that enable more efficient delivery of 
cargo, such as proteins, as tools to probe intracellular pathways.  
3.2. Materials and Methods 
3.2.1. PTDM Synthesis 
3.2.1.1. Monomers 
Similar to monomer synthesis in section Error! Reference source not found., all f
ive monomers were synthesized following the procedure introduced by Lienkamp et. al.192 
In general, the Diels-Alder adduct 1 was obtained by the reaction of maleic anhydride with 
furan in toluene. As following Lienkamp et al., the monomers were synthesized from 1 
under similar conditions: 
 
dG: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of 1,2-Di-
Boc-2-ethyl guanidine, and 10 mol% 4-dimethylaminopyridine (DMAP). The temperature 
was lowered to 0°C with an ice bath and 1 eq. of 1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide (EDC) was added, then stirred over night at room 
temperature. After completion of the reaction, the solution was concentrated and the 
product was purified via column chromatography with silica gel using DCM/ethyl acetate 
(8:2) as eluent. Vacuum evaporation of the solvent yielded the pure product with a yield of 
~60%.  
1H NMR (300 MHz, CD3CN): δ 11.54 (s, 2H), 8.35 (s, 2H), 6.44 (s, 2H), 5.17 (s, 2H), 4.33 
– 3.97 (m, 4H), 3.72 – 3.41 (m, 4H), 2.82 (s, 2H), 1.48 (s, 9H), 1.42 (s, 9H); 13C NMR (75 
MHz, CD3CN): δ 172.43, 164.51, 157.35, 153.72, 137.56, 84.05, 81.41, 79.50, 63.72, 
47.49, 40.21, 28.38, 28.09; HR-MS (FAB) m/z [M+H]+: 755.3827 (calc.), 755.3824 
(found). 
MeG: 1 was dissolved in the minimum amount of dry DCM together with 1 eq. of 1,2-Di-
Boc-2-ethyl guanidine, and 10 mol% DMAP. The temperature was lowered to 0°C with an 
ice bath and 1 eq. of EDC was added, then stirred over night at room temperature. The half 
ester was precipitated from solution, isolated using vacuum filtration, and washed with 
cold DCM followed by drying on vacuum overnight. The half ester, one equivalent of 
MeOH. and 10% DMAP were dissolved in DCM and stirred at RT under nitrogen. After 
completion of the reaction, the solution was concentrated and the product was purified via 
column chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum 
evaporation of the solvent yielded the pure product with a yield of ~80%.  
1H-NMR (300 MHz, CDCl3): δ=11.50 (1H, s), 8.55 (1H, s), 6.46 (2H, s), 5.3 (2H, d, J=6.0 
Hz), 4.25 (2H, m), 3.72 (5H, m), 2.84 (2H, s), 1.49 (18H, s).13C-NMR (75 MHz, CDCl3): 
δ= 171.7, 171.5, 163.4, 156.3, 153.1, 136.6, 83.2, 80.7, 80.6, 79.4, 63.5, 52.4, 47.1, 46.6, 
39.4, 28.3, 28.1. HR-MS (FAB): calc. 483.22, found 484.23. 
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dPh: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of benzyl 
alcohol, and 10 mol% DMAP. The temperature was lowered to 0°C with an ice bath and 1 
eq. of EDC was added, then stirred over night at room temperature. After completion of 
the reaction, the solution was concentrated and the product was purified via column 
chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum 
evaporation of the solvent yielded the pure product with a yield of ~88%.  
1H NMR (300 MHz, CD3CN): δ 7.34 (d, J = 3.0 Hz, 10H), 6.44 (s, 2H), 5.16 (s, 2H), 4.97 
(dd, J = 45.5, 12.4 Hz, 4H), 2.87 (s, 2H); 13C NMR (75 MHz, CD3CN): δ 172.37, 137.52, 
137.03, 129.41, 129.14, 129.06, 81.30, 67.26, 47.58; HR- MS (FAB) m/z [M+H]+: 
365.1389 (calc.), 365.1398 (found). 
MePh: One equivalent of 1 and 1.25 equivalents of the corresponding substituted benzyl 
alcohol, and 10 mol% DMAP were dissolved in minimal amounts of distilled DCM and 
the reaction mixture was stirred under nitrogen at room temperature overnight. The half 
ester was precipitated from solution, isolated using vacuum filtration, and washed with 
cold DCM followed by drying on vacuum overnight. The half ester, one equivalent of 
MeOH. and 10% DMAP were dissolved in DCM and stirred at RT under nitrogen. The 
solution was then cooled down to 0˚C and one equivalent of EDC was added. The solution 
as stirred overnight under nitrogen at room temperature. The reaction mixture was then 
collected by rotoevaporation and purified by column chromatography with DCM/ethyl 
acetate (8:2). the sample was dried under vacuum over night to obtain a pure white solid 
(yield 82%). 
1H NMR (300 MHz, CD3CN): δ = 7.38 (comp, 5H), 6.44 (comp, 2H), 5.14 (d, 2H), 5.06 
(comp, 2H), 3.50 (s, 3H), 2.84 (q, 2H).13C NMR (75 MHz, CD3CN): δ = 173.35, 172.84, 
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137.95, 137.91, 137.51, 129.84, 129.60, 129.50, 81.64, 81.63, 67.72, 52.75, 47.96, 47.89. 
HR-MS (FAB) m/z [M+H]+: 289.1076 (calc.), 289.1078 (found). 
dMe: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of MeOH, 
and 10 mol% DMAP. The temperature was lowered to 0°C with an ice bath and 1 eq. of 
EDC was added, then stirred over night at room temperature. After completion of the 
reaction, the solution was concentrated and the product was purified via column 
chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum 
evaporation of the solvent yielded the pure product with a yield of ~84% (6).  
1H NMR (500 MHz, DMSO): δ = 6.46 (s, 2H), 5.11 (s, 2H), 3.55 (s, 6H), 2.82 (s, 2H). 13C 
NMR (125 MHz, DMSO): δ = 171.70, 136.61, 79.74, 51.63, 46.23. HR-MS (FAB) m/z 
[M+H]+: 213.0763 (calc.), 213.0749 (found). 
3.2.1.2. Polymers 
Reaction conditions for block copolymer synthesis: Monomer dG, monomer 
MePh, and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged 
with nitrogen, and subjected to three freeze-pump-thaw cycles. Monomer dG solution was 
added into the catalyst solution via syringe all at one time. The brown solution was stirred 
for 30 minutes at room temperature before monomer MePh was introduced. After stirring 
for an additional 2 hours, the reaction was terminated with 1 mL of ethyl vinyl ether and 
stirred for 30 minutes. DCM was evaporated and the product was dissolved in minimal 
DCM and loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted 
end-group and any side products were washed from the column with DCM, while polymer 
remained on the column and was recovered with ethyl acetate. Ethyl acetate was 
evaporated to yield the pure product. Block co-polymers were characterized by 1H NMR 
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along with THF GPC using a polystyrene standard (Error! Reference source not found.) t
o determine block length and ratio. 
 
 
dPh5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.66 (2H, br), 8.47 (2H, br), 7.32 (12H, 
br), 5.98 (trans) and 5.68 (cis) (4H total, br), 5.21 (4H, br), 5.01 (cis) and 4.74 (trans) (4H 
total, br), 4.25 (4H, br), 3.69 (4H, br), 3.27 (4H, br), 1.46 (18H, s), 1.41 (18H, s).  
MePh10-b-dG5: 1H-NMR (500 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H, 
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H 
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 1.46 (18H, 
s), 1.41 (18H, s).  
 
dPh5-b-MeG10: 1H-NMR (500 MHz, CDCl3): d 11.52 (1H, br), 8.31 (1H, br), 7.33 (12H, 
br), 5.84 (trans) and 5.60 (cis) (4H total, br), 4.99 (4H, br), 4.90 (cis) and 4.60 (trans) (4H 
total, br), 4.17 (2H, br), 3.62 (3H, br), 3.49 (2H, br), 3.13 (4H, br), 1.44 (9H, s), 1.41 (9H, 
s).  
MePh10-b-MeG10: 1H-NMR (500 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.34 (6H, 
br), 5.82 (trans) and 5.61 (cis) (4H total, br), 5.03 (2H, br), 5.00 (cis) and 4.76 (trans) (4H 
total, br), 4.59 (2H, br), 4.14 (6H, br), 3.62 (2H, br), 3.51 (4H, br), 3.14 (9H, br), 1.44 (9H, 
s), 1.40 (18H, s).  
dPh10-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.56 (2H, br), 8.39 (2H, br), 7.33 (12H, 
br), 5.88 (trans) and 5.62 (cis) (4H total, br), 5.10 (2H, br), 5.03 (cis) and 4.66 (trans) (4H 
total, br), 4.18 (2H, br), 3.60 (4H, br), 3.15 (4H, br), 1.46 (18H, s), 1.43 (18H, s).  
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MePh5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.66 (2H, br), 8.47 (2H, br), 7.32 (6H, 
br), 5.98 (trans) and 5.68 (cis) (4H total, br), 5.21 (4H, br), 5.01 (cis) and 4.74 (trans) (4H 
total, br), 4.25 (4H, br), 3.69 (4H, br), 3.27 (4H, br), 1.46 (18H, s), 1.41 (18H, s).  
dMe5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.59 (2H, br), 8.39 (2H, br), 5.93 (trans) 
and 5.67 (cis) (4H total, br), 5.08 (4H, br), 4.90 (cis) and 4.70 (trans) (4H total, br), 4.23 
(6H, br), 3.65 (4H, br), 3.18 (4H, br), 1.46 (18H, s), 1.41 (18H, s).  
dMe10-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.56 (2H, br), 8.38 (2H, br), 5.89 
(trans) and 5.59 (cis) (4H total, br), 5.07 (4H, br), 5.96 (cis) and 4.69 (trans) (4H total, br), 
4.21 (6H, br), 3.61 (4H, br), 3.22 (4H, br), 1.51 (18H, s), 1.47 (18H, s).  
Table 0.1. Molecular weight of polymer series determined by gel permeation 
chromatography in tetrahydrofuran (THF) using a polystyrene standard. 
Polymer Mn Mw Mp PDI 
dPh5-b-dG5 9488 10123 10103 1.067 
MePh10-b-dG5 5612 6071 6166 1.082 
dPh5-b-MeG10 9965 10609 10782 1.065 
MePh10-b-MeG10 11063 12060 12277 1.090 
dPh10-b-dG5 9496 10265 10565 1.081 
MePh5-b-dG5 5412 5744 5743 1.061 
dMe5-b-dG5 5078 5392 5438 1.062 
dMe10-b-dG5 6366 7011 7380 1.10 
3.2.1.3. Deprotection 
The polymers were dissolved in 2 mL DCM and 2 mL trifluoroacetic acid (TFA) 
for deprotection. After stirring overnight, the excess acid was removed by azeotropic 
distillation with methanol. After complete evaporation of the acid, samples were dissolved 
in water/methanol mixture and dialyzed against RO water until the conductivity of water 
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was ~0.1µS. The deprotected copolymer was recovered by lyophilization. Final 
deprotected polymer was stored at -20 ºC. 
3.2.2. Characterization 
3.2.2.1. Reverse Phase High Liquid Chromatography 
Water and acetonitrile were each prepared with 0.1% TFA for the liquid phase. 
Monomers were prepared at 5 mg/mL in DMSO, which also served as the flow marker. 
Samples were loaded onto a C8 reverse phase column held at room temperature and run at 
a gradient of 100% water to 100% acetonitrile over 60 minutes. Each sample was followed 
by 15 minutes of equilibration back to water prior to loading of the next sample.  
3.2.2.2. Dynamic Light Scattering 
dPh10-b-dG5, MePh10-b-dG5, and dMe10-b-dG5 were dissolved in DMSO and 
brought to a final concentration of both 5 mg/mL and 2.5 mg/mL. Samples were subjected 
to dynamic light scattering (DLS) at 10 degree intervals between 30 and 90 degrees. An 
exponential decay was fit to the data to calculate the Rg values of the polymers. Exponential 
fits can be found in Figure 0.4. 
3.2.3. Protein Delivery 
3.2.3.1. Suspension Cells 
Jurkat T cells, a human T lymphocyte leukemia cell line (clone E6-1, ATCC TIB-
152), were grown in RPMI 1640 supplemented with 10%(v/v) FBS, L-glutamine, non-
Essential amino acids (NEAA), Na-pyruvate, 100 U/mL penicillin, and 100 U/mL 
streptomycin at 37˚C, 5% CO2 and were passaged 24 hours before treatment. Polymers 
were mixed with 2 µg of EGFP at a ratio of 20:1 polymer to protein and allowed to complex 
for 30 minutes. Jurkats were harvested and suspended in fresh complete media and placed 
into a 12 well plate at 4X105 cells/mL. PTDM – protein complexes were applied drop-wise 
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into each well. Cells were treated for 4 hours, then washed 3 times with 20 U/mL heparin 
in PBS before being suspended in 0.2% BSA FACS buffer and stained with 7-AAD. EGFP 
internalization and viability were assessed by flow cytometry using a BD® LSR-II. EGFP 
fluorophores were excited at 488 nm, and fluorescence was measured at 530 nm. The 
fluorescence signal was collected for 10,000 cells and viable cells were gated on to obtain 
a histogram of fluorescence intensity per cell. Live cells were assessed for their median 
fluorescence intensity (MFI) and their total positive shift in fluorescence (% positive). 
Internalization and delivery was repeated in three independent experiments. Statistical 
analysis was performed using the one way ANOVA and Tukey post hoc test to determine 
significance between polymers. 
3.2.3.2. Adherent Cells 
HeLa (human) and hTERT mesenchymal stem cells (MSCs) were grown at 37˚C 
with 5% CO2 in DMEM supplemented with 10%(v/v) FBS, 100 U/mL penicillin, and 100 
U/mL streptomycin. Cells were plated at 5X104 cells/mL in a 12 well plate 48 hours before 
treatment for FACS analysis or 1X106 cells in a 35 mm glass bottom plate for CLSM. 
Polymers were mixed with 2 µg of EGFP at a molar ratio of 20:1polymer to protein and 
allowed to complex for 30 minutes during which cells were aspirated and covered in fresh 
complete media. PTDM–protein complexes were applied drop-wise into each well. After 
4 hours of treatment, cells were aspirated and lifted with 0.1% trypsin, then treated with 
complete media to bind excess trypsin. Cells were then washed 3 times with 20 U/mL 
heparin in PBS before being suspended in 2% FBS FACS buffer and stained with 7-
aminoactinomycin D (7-AAD). Similar to the Jurakts, EGFP internalization and viability 
were assessed by flow cytometry under the same conditions.  
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3.2.3.3. Confocal Laser Scanning Microscopy 
HeLa cells were seeded at 106 cells/ 2 mL of a-MEM with 10% FBS on 35 mm 
glass bottom plates and 105 cells/ 1 mL on 12-well plates 48 hours prior to treatment and 
cultured at 37˚C and 5% CO2. Polymer was complexed with 2 µg of protein at a ratio of 
20:1 polymer to protein for 30 minutes, during which the cells were aspirated and covered 
in fresh complete media. Cells were treated for 4 hours with the polymer protein complexes 
in a total volume of 1 mL a-MEM with 10% FBS. Before imaging, cells were washed three 
times with cold media and covered in 1 mL fresh cold a-MEM with 10% FBS. Cells were 
imaged using a FV300 CSLM Olympus IX81 microscope at 60X. 
3.3. Results and Discussion 
3.3.1. PTDM Design 
The presence of guanidinium groups and hydrophobic moieties in PTDs and 
PTDMs has previously been reported as crucial for protein delivery.194 To investigate the 
role of hydrophobicity and charge density, a series of monomers with varying hydrophobic 
and cationic content was synthesized (Figure 0.1). The hydrophobic magnitude of 
monomers in Figure 0.1B was assessed using reverse phase HPLC. The di-methyl (dMe) 
monomer had the lowest retention time (13.8 minutes), whereas methyl-phenyl (MePh), 
with an added benzene ring, had an intermediate retention time (27.5 minutes) and the di-
phenyl monomer (dPh) had the longest retention time (35.9 minutes) (Error! Reference s
ource not found.). These retention times indicate that the addition of phenyl groups to the 
monomer increases hydrophobic content and is thus translatable to the hydrophobic content 
of the polymers. Two guanidine containing monomers, methyl-guanidine (MeG) and di-
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guanidine (dG), were also designed in order to investigate the role of cationic density 
within the positively charged block of the polymers.  
 
Figure 0.1. Oxanorbornene monomers used in this study. A) Guanidine containing 
monomers methyl guanidine (MeG) and di-guanidine (dG), with blue representing 
the cationic substituent and grey for the added methyl. B) Hydrophobic monomers 
di-methyl (dMe), Methyl-phenyl (MePh), and di-phenyl (dPh), with green 
representing the most hydrophobic components. C) Reverse-phase HPLC 
chromatographs for dMe, MePh, and dPh monomers elucidating relative 
hydrophobicity. 
These difunctional monomers were polymerized by ROMP to yield low dispersity 
(Ɖ) oxanorbornene block copolymers. GPC traces showed a complete shift in the final 
diblock toward a higher molecular weight compared to the first block, illustrating 
controlled polymerization for efficient chain extension. All polymers had narrow Ɖ values 
(≤ 1.1) as determined by GPC, and a phenyl to guanidine ratio consistent with expectations, 
as determined by 1H NMR spectroscopy.  
10 15 20 25 30 35 40 45
0
0.2
0.4
0.6
0.8
1
Retention Time (Min)
No
rm
al
ize
d 
In
te
ns
ity
 
 
dPh
MePh
dMe
O
O CH3
O
O
O
CH3
O
O
O
O
O
O
O
O
O
O
CH3
H
N
NHBoc
NBoc
O
O
O
O
O
CH3
H
N
NHBoc
N
H NHBoc
NBoc
NBoc
O
O
O
O
O
 
dMe MePh dPh 
MeG dG 
 
A 
B 
C 
 76  
A series of four block copolymers was created comprised of a first block with ten 
phenyl substituents and a second block with ten guanidine substituents. Within these 
samples, however, the density of these functional groups is varied using the smallest methyl 
substituent to add space between hydrophobic or cationic groups. These are depicted in 
Figure 0.2 as dPh5-b-dG5, MePh10-b-dG5, dPh5-b-MeG10, and MePh10-b-MeG10. This 
set of polymers was designed to explore the effect of varying charge and hydrophobic 
density along the polymer backbone on the ability of the PTDMs to deliver protein into 
HeLa, hTERT MSC, and Jurkat T cells.  
 
Figure 0.2. Structures and cartoons of a polymer series with varying cationic and 
hydrophobic density. Each polymer contains 10 phenyl groups represented in green 
and 10 guanidinium groups represented in blue. The density of the hydrophobic and 
cationic groups is varied using a methyl substituent (grey). 
To further investigate the effect of hydrophobic moieties and backbone contribution 
on protein delivery, the series was expanded to include another set of polymers that hold 
the high guanidinium density (dG5) constant but vary hydrophobic density (either dPh, 
MePh, or dMe) and length (5 or 10) to compliment the initial polymer set. For example, 
dPh10-b-dG5 has high hydrophobic density (dPh) with a length of ten to match the 
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backbone length of the longest hydrophobic block (MePh10-b-dG5); MePh5-b-dG5 was 
added to distinguish between added backbone length and decreased hydrophobic density 
(juxtapose MePh10-b-dG5 and dPh10-b-dG5); lastly, dMe5-b-dG5 and dMe10-b-dG5 were 
included as controls to mimic the length of the backbone added by the hydrophobic blocks, 
while minimizing the hydrophobicity of the substituents. This second series of other 
polymers, displayed in Figure 0.3, was specifically designed to decouple hydrophobic 
block length from hydrophobic content with respect to protein delivery.  
 
Figure 0.3. Structures and cartoons of the second polymer series with varying 
hydrophobic density and length. dPh5-b-dG5 and MePh10-b-dG5 are repeated from 
Figure 0.2 for ease of comparison. Hydrophobic phenyl substituents are represented 
in green, cationic moieties in blue, and methyl groups in grey.  
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3.3.2. Dynamic Light Scattering 
Dynamic light scattering was performed on dPh10-b-dG5, MePh10-b-dG5, and 
dMe10-b-dG5 to determine whether these molecules self-assemble in an aqueous 
environment Figure 0.4. These three polymers were chosen to compare the maximum 
hydrophobic block lengths with varying phenyl group density. While this is not a direct 
indication of their ability to interact with cargo or transverse the membrane, it is important 
to understand whether they present a “hydrophobic core” in which the protein might reside 
or act as individual, solvated chains. dMe10-b-dG5 had an Rh of 33 nm, MePh10-b-dG5 had 
an Rh value of 67 nm, and the relaxation curves (Figure 0.4) for dPh10-b-dG5 indicated a 
polydisperse Rh fit of 29 nm showing that all three block copolymers self-assemble in 
aqueous solution. Given that the overall sizes are similar despite the variation in 
hydrophobic side chain suggests that the overall block architecture is more important to 
driving assembly than the side chain composition. Both polymers containing phenyl side 
chains had broader distributions, so it is possible that the side chains have some influence 
on the nanoparticles internal organization. Nevertheless, from these findings it can be 
hypothesized that the self-assembled aggregates provide a hydrophobic domain that allows 
the polymers to complex their cargo while the role of electrostatic interactions remains 
unclear given the phosphate buffer solution in which they are formed contains around 150 
mM of salt. 
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Figure 0.4. Dynamic light scattering curves (top) for dMe10-dG5, MePh10-dG5, and 
dPh10-dG5 overlayed with their CONTIN fits (bottom) used to predict the radius of 
hydration. Measurements were taken at 30˚, 40˚, 50˚, and 60˚ and used together for 
the prediction. 
3.3.3. Protein Delivery 
The ability of the polymers to facilitate the internalization of EGFP into cells was 
investigated in Jurkat T cells, HeLa cells, and hTERT MSCs. To assess protein delivery 
and viability, cells were analyzed using flow cytometry. In addition, confocal microscopy 
was used to image uptake into HeLa cells for the first series of polymers (Figure 0.2). 
Trends were relatively consistent across the three cell lines with respect to their percent 
uptake, median fluorescence intensity (MFI), and viability profiles. While all polymers 
tested were able to deliver consistently into greater than 50% of the cell populations (SI), 
the amount of protein delivered, determined by MFI, varied based on the polymer and, to 
a limited extent, cell type. Cell viability was above 95% in both HeLa and Jurkats, but 
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slightly decreased to just above 80% for dPh5-b-dG5 and MePh10-b-dG5 in the hTERT 
MSCs as seen in Figure 0.5. 
 
Figure 0.5. Cellular viability after cells were treated with 2 µg of protein at a 20:1 
polymer to protein molar ratio for 4 hours, as determined by 7AAD staining 
compared with an untreated sample. Viability is above 90% in all cases, except with 
the MePh10-dG5 and dPh10-dG5 in the hTERT MSCs which are higher than 85%.  
The MFI (Figure 0.6) in all cell types, as established by flow cytometry, showed 
that MePh10-b-dG5, containing the high cationic density dG monomer, yielded greater 
internalization than its counterpart, MePh10-b-MeG10, with the MeG monomer. This 
indicates that increasing the cationic density of the block copolymer improves protein 
internalization, corroborating the suggestion that high guanidine density is important for 
membrane interactions and therefore delivery.187 It should be noted that while there was no 
statistical difference between delivery using dPh5-b-dG5 and dPh5-b-MeG10, the 
fluorescent shift appears higher for the more cationically dense polymer (dPh5-b-dG5) in 
Jurkats, suggesting that similar correlations could be drawn from this more sensitive cell 
line. These findings were additionally confirmed by images taken with CLSM of HeLa 
cells treated with the polymer-protein complexes, Figure 0.7, which revealed both punctate 
and diffuse fluorescence within the cells.  
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Figure 0.6. Representative histograms (top) compared to a blank (grey) and the 
corresponding median fluorescence intensity (bottom) for EGFP delivery with 
MePh10-b-MeG10, MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5 into HeLa, Jurkat 
T cells, and hTERT MSCs. Cells were treated with 2 µg of protein at a 20:1 polymer 
to protein molar ratio for 4 hours, then washed with heparin to remove membrane 
bound proteins. A shift to the right from the grey blank in the histograms indicates 
higher fluorescence and was used to establish the median fluorescence intensity (MFI) 
as well as the percent uptake.  
While all four polymers yielded a complete shift in the fluorescence population of 
the cells, the MFI was 10X higher when using MePh10-b-dG5 in all three cell types. 
Surprisingly, increasing hydrophobic density did not improve the ability of the polymers 
to deliver protein into any of the cell types, as seen by comparing dPh5-b-dG5 with 
MePh10-b-dG5. With MePh10-b-dG5 able to deliver the most protein (MFI ranging 
between 3000 to 4000) into the highest percentage of cells (around 95% depending on the 
cell type), high cationic density coupled with a lower density hydrophobic block appeared 
to optimize protein internalization. However, these comparisons alone do not fully 
decouple hydrophobic density of the monomer functional groups from potential 
hydrophobic effects related to the length. To explore this specific relationship, the series 
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was expanded to include dPh10-b-dG5, MePh5-b-dG5, dMe5-b-dG5, and dMe10-b-dG5, as 
shown in Figure 0.3.  
 
Figure 0.7. CLSM images of EGFP delivery into HeLa cells by MePh10-b-MeG10, 
MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5. Cells were treated with 2 µg of 
protein at a 20:1 polymer to protein ratio for 4 hours, and then washed 3 times to 
remove excess protein. 
These polymers all contain a cationic dG block length of 5, since high cationic 
density appears to be more optimal for protein delivery. Higher internalization was seen 
when the dPh block length was increased from 5 to 10 (dPh10-b-dG5) yielding a higher 
MFI and effecting a higher percentage of the cell population in all cell types. Decreasing 
the MePh block length from 10 to 5 (MePh5-b-dG5) reduced delivery and the percentage 
of cells that received protein. More specifically, in Jurkats but not HeLa or the MSCs, there 
is an added advantage of using dPh10-b-dG5 as it results in almost two fold higher MFI 
than MePh10-b-dG5. This difference highlights the tunability of this polymer platform to 
address specific cell types. Any additional hydrophobicity introduced by increasing the 
length of the polymer was investigated by replacing the phenyl substituents with methyl 
dPh5-b-dG5 MePh10-b-dG5 
MePh10-b-MeG10 dPh5-b-MeG10 
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groups (dMe5-b-dG5 and dMe10-b-dG5). These polymers showed moderate protein 
delivery to a high number of cells, but the amount of protein delivered was far less than 
their phenyl containing counterparts (Figure 0.8). This indicates that, in addition to 
increased block length, the presence of a threshold hydrophobicity is important for efficient 
cellular internalization of this cargo. 
 
 
Figure 0.8. Representative histograms and the corresponding median fluorescence 
intensity for EGFP delivery with dMe5-b-dG5, dMe10-b-dG5, MePh5-b-dG5, MePh10-
b-dG5, dPh5-b-dG5, and dPh10-b-dG5 into HeLa, Jurkat T cells, and hTERT MSCs. 
Cells were treated with 2 µg of protein at a 20:1 polymer to protein molar ratio for 4 
hours, then washed with heparin to remove membrane bound proteins. A shift to the 
right from the grey blank in the histograms indicates higher fluorescence and was 
used to establish the median fluorescence intensity (MFI) as well as the percent 
uptake. 
The ability to deliver proteins is substantially amplified when the hydrophobic 
block length is increased for the two phenyl-containing monomers (MePh, dPh), 
regardless of cell type. Both adherent cell types showed insignificant differences in MFI 
between MePh10-b-dG5 and dPh10-b-dG5, while Jurkats were sensitive to the hydrophobic 
substituents with dPh10-b-dG5 outperforming MePh10-b-dG5. Further investigation with 
Jurkats HeLa  MSCs 
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other cell types, both adherent and suspension, might provide insight into this difference. 
Additionally, other polymer series with different hydrophobic substituents may help 
determine if the aromaticity of the phenyl group is indeed crucial, or cell type dependent. 
Lastly, optimization with different cargos would allow for further development and 
specificity of this polymer platform for increased internalization of proteins and antibodies 
into hard to transfect cell types. 
3.4. Conclusion 
Oxanorbornene block copolymers with varying cationic and hydrophobic density 
but the same charge and hydrophobic content were synthesized and characterized. While 
all of the PTDMs displayed the ability to deliver protein into HeLa, Jurkats, and hTERT 
MSCs, increased cationic density proved to have a slight edge over those with a methyl 
substituent on each guanidinium-based monomer. A second series of polymers highlighted 
the importance of hydrophobic length over density, although additional hydrophobicity 
from increasing the polymer backbone length does not exceed the hydrophobic threshold 
that is required for protein internalization. Increasing the length of the hydrophobic blocks 
may introduce better PTDM–protein interactions, facilitating delivery across the 
membrane. Further studies using different cargo types such as intracellularly active 
proteins would highlight the capabilities of these block copolymers. 
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CHAPTER 4 
SERUM SENSITIVE PROTEIN DELIVERY BY POLYMERIC PEPTIDE 
MIMICS 
4.1. Introduction 
The field of transfection has been dominated by the delivery of DNA for 
constitutive expression within the cell. The delivery of proteins into the cytosol can be 
exploited to produce highly specific intracellular interactions with spatial and temporal 
control.6 Results from protein transfection can be extremely fast in comparison with 
traditional gene expression as it does not require transcription and translation.226 The 
temporal control allows for investigation of transient effects of proteins, while avoiding 
over expression or random insertion of DNA into the targeted genome.8 Protein and 
antibody delivery into the cytosol provide a platform to probe intracellular pathways 
involved in protein expression, transcriptional regulation, cell cycle, as well as many 
others.26  
To date, the concept of protein delivery has been predominantly addressed by viral 
transfection, electroporation, and liposomal carriers.6 While relatively effective, these 
techniques have severe limitations such as high toxicity and low efficiency that have been 
addressed by the development of a category of protein delivery vehicles based on cationic 
polymeric systems.7,8,114,227 While several polymer systems are currently commercially 
available, often they are limited in their cargo variety, as well as the type of cell they are 
able to deliver into. Additionally, almost all delivery platforms require serum free 
conditions, which can be detrimental to the viability of the cells. Herein, we compare a 
variety of commercially available amphiphilic polymers and peptides in their ability to 
deliver GFP into HeLa, HUVEC, hTERT mesenchymal stem cells, and Jurkat T cells in 
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both serum free and complete media. While most of the reagents are proprietary, the 
following are descriptions of each of the carriers from their respective manufacturers.  
4.1.1. Pep-1 
Pep-1 was first reported by Morris et. al. to deliver proteins intracellularly using 
non-covalent interactions with the macromolecule of interest.119 Since then Pep-1 and its 
derivatives have been patented and are now marketed by Active Motif® under the name 
Chariot™. Chariot™ claims delivery efficiency between 60-95% in less than two hours 
after delivery, at which time live cells can be assayed to determine the effects of the 
introduced material, without the need for fixing. According to Morris et. al. and Active 
Motif®, the peptide stabilizes the protein, reducing degradation and preserving its natural 
characteristics during delivery.118,119,161 After delivery, the complex dissociates, leaving the 
macromolecule biologically active and free to proceed to its target organelle. Previous 
reports indicate delivery occurs in the presence or absence of serum and is independent of 
the endosomal pathway, which can modify macromolecules during internalization.228 
Additionally, Chariot™ boasts low toxicity to the cells being transfected.  
4.1.2. PULSin 
PULSin™ is a cationic amphiphilic reagent designed by Polyplus Transfection® 
for the delivery of peptides, antibodies and proteins into cells. The proprietary formulation 
claims efficient delivery of anionic proteins and antibodies into a large variety of 
eukaryotic cell lines and primary cells. PULSin™ is most efficient when able to interact 
with the protein by electrostatic and/or lipophilic interactions. According to Polyplus 
Transfection®, complexes are internalized via anionic cell-adhesion receptors and are 
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released into the cytoplasm where they disassemble. The process is non-toxic and delivers 
functional proteins, without the requirement of fixation.  
4.1.3. ProteoJuice 
ProteoJuice™ is a reagent produced by Novagen® owned by MerckMillipore® for 
the introduction of intact functional protein into mammalian cells. ProteoJuice™ forms 
non-covalent interactions with protein and has endosome protective properties ensuring 
delivery of intact protein within the cell. ProteoJuice™ is compatible with delivery of 
peptides and small proteins, large proteins, and even multimeric protein complexes with 
minimal toxicity and broad cell specificity. Live cells can be examined less than two hours 
after delivery to determine the effects of the introduced material without the need for cell 
fixation.  
4.1.4. Xfect 
The Xfect™ Protein Transfection Reagent uses a cell-penetrating peptide 
developed at Clontech® to bind and transport active proteins directly into a wide variety 
of mammalian cell types, including hard-to-transfect human suspension cell lines and 
mouse embryonic stem cells. Xfect™ is a modified peptide with cell-penetrating activity 
whose amino acid composition enables it to interact with a protein cargo and transport this 
protein across a cell membrane barrier within 2 hours. 
4.1.5. Protein Transduction Domain Mimics 
The amphiphilic polymeric protein transduction domain mimic (PTDM) MePh10-
b-dG5 was designed to mimic cell penetrating peptides incorporating a dense block of 
guanidine, known for its ability to permeate cell membranes, attached to a hydrophobic 
block, which has been shown to facilitate cargo delivery.134,135,229,230 Here, the 
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nomenclature MePh refers to a block that contains monomers that have methyl and phenyl 
substituents, and dG is constituted of two guanidine groups per monomer imparting dense 
cationic charge. The Tew group has previously shown proof of concept for cellular uptake 
of similar PTDMs using a fluorescent label and subsequent delivery of proteins, peptides, 
and antibodies into Jurkat T cells as well as primary cells.115,134,136,187,191,229–232 The 
amphiphilic nature of this PTDM allows it to form a non-covalent complex with the desired 
cargo and facilitate its transport across the cell membrane in both complete media and 
serum free conditions with low cytotoxicity. Internalization of the cargo has been tested as 
early as 4 hours after delivery and protein function has been recorded out to 72 hours.  
4.2. Materials and Methods 
A total of five cationic polymer delivery vehicles were tested for their ability to 
deliver GFP into a variety of cell types. Specifically, the commercially available Pep-1, 
also known as Chariot™, ProteoJuice™, PULSin™, and Xfect™ were compared with our 
amphiphilic polymeric peptide mimic, herein referred to as the protein transduction domain 
mimic (PTDM), in both complete and serum free conditions. All purchased delivery 
reagents claim non-covalent interactions with their cargo and broad cell specificity.  
A variety of human cell lines were chosen to demonstrate translation across cell 
types: HeLa, HUVEC, Jurkat, and hTERT mesenchymal stem cells (MSCs). HeLa cells 
are the oldest and most commonly used adherent cell line and are used in many research 
fields due to their stability and relative ease of transfection. HUVECs are derived from the 
endothelium of veins from a human umbilical cord and have different surface properties 
than many other cell lines. Jurkat T cells are a suspension cell line of T cells that have 
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proven difficult for many transfection reagents. Lastly, we used MSCs as a proof of concept 
cell type whose differentiation could be affected by protein cargo delivery.  
To assess the ability of protein delivery, GFP was chosen as a cargo as it is self-
reporting and readily accessible to most laboratories. The amount of protein delivered was 
held constant at 2 µg so that the different reagents could be compared to one another. 
Uptake was assessed by flow cytometry after treatment with the complexes and subsequent 
washing of the cell surface with trypsin followed by three heparin washes (20 U/mL) to 
remove any complexes stuck to the cell surface. 
The commercial reagents all required some optimization regarding the ratio of 
reagent to protein cargo, incubation time, and cell density to improve their ability to deliver 
specific proteins. Delivery conditions were optimized for each of the reagents using HeLa 
and Jurkat T cells and translated across the other cell types. All adherent cells were plated 
24 hours prior to transfection at respective cell densities to achieve 70-90% confluency at 
the beginning of the experiment. 
Even though some of the reagents claim the ability to deliver in complete media, 
most suggest removal of any exogenous protein during the actual transduction. Several 
suggest washing the cells up to three times with PBS to remove the presence of serum. To 
accommodate this, delivery was performed on cells that had been washed two times with 
PBS and then suspended with serum free media. Optimization regarding serum free 
conditions revealed higher viability (using 7-AAD) if cells were treated for 2 hours and 
then supplemented with complete media for an additional 2 hours. A comparison of the 
reagents was also made in complete media (10% FBS) to show the effect of the presence 
of serum on uptake.  
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4.3. Results and Discussion 
As measured by a shift in cell fluorescence in relation to the untreated control (% 
Positive), all of the commercial reagents except Chariot™ were able to deliver GFP into 
all four cell types effecting 80% or less of the cells as shown in Figure 0.1. As expected, a 
reduction in percent positive cells was observed when the complex delivery was done in 
the presence of complete media. In contrast, the median fluorescence intensity (MFI), 
which is directly proportional to the amount of protein delivered was exceptionally low for 
all the commercial carriers in all cell types indicating that while they were able to target 
many cells, they were not able to deliver large amounts of protein into the cells.  
 
Figure 0.1. Delivery efficiency of 2 µg GFP into Jurkats, HeLa, hTERT mesenchymal 
stem cells, and human umbilical vein endothelial cells after 4 hours of treatment in 
serum free conditions or complete media with amphiphilic polymers designed for 
non-covalent delivery. The top row shows the median fluorescence intensity, 
signifying the amount of protein that was delivered into the cells, while the bottom is 
the percentage of cells that were positive for the fluorescent cargo. Data is displayed 
as the mean and SEM of three replicates.  
Chariot™ showed no delivery of GFP into any of the cell types in either serum free 
or complete media. Extra effort was spent optimizing for this carrier with GFP, but 
regardless of conditions, it never showed substantial uptake or increase in MFI. This could 
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be related to the nature of the cargo and its subsequent interactions with the peptide, since 
the manufacture claims it can deliver b-galactosidase efficiently into a variety of cell types.  
Moderate delivery was achieved using PULSin™, especially in serum free 
conditions delivering into 40-80% of the cells. The positive shift was muted in the presence 
of serum, with a smaller positive shift shown in HUVEC and MSCs. While there was a 
small shift in MFI from the blank in all cell types for PULSin, it appears that the relative 
shift was low when compared with the PTDM. Serum free conditions appeared to facilitate 
delivery, suggesting that PULSin might not bind to the GFP very strongly and that it can 
easily swap out serum proteins for the fluorescent cargo. Alternatively, the serum proteins 
may help inhibit interactions with the cell membrane.  
ProteoJuice™ was largely ineffective in the HeLa and HUVEC cell types but 
showed around 20% delivery into Jurkats and MSCs. Uptake was not reflected in the MFI, 
where ProteoJuice appears to only deliver a small amount of GFP into any of the cell types. 
Unfortunately, the cell viability in Jurkats was greatly reduced in serum free conditions for 
this reagent (Figure 0.2).  
Xfect™ performs well in serum free conditions, delivering in up to 60% of Jurkats, 
though the MFI of those cells remains low indicating low amounts of protein are delivered 
into the GFP positive cells across all cell types. Only in MSCs does Xfect™ show any 
delivery in complete media.  
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Figure 0.2. Viability as determined by 7-AAD of the cells treated with the protein-
carrier complexes in both serum free (blue) and complete media (red). Samples were 
normalized against the untreated control and the mean ± SEM is shown for three 
separate experiments.  
Most notably, the PTDM used here could deliver into a high percentage of all cell 
types in both serum free and serum containing conditions and had a large shift in MFI, 
indicating that most of the cells were receiving a large portion of protein. As seen with the 
other transfection reagents, the presence of serum slightly hampers the delivery of GFP. A 
decrease in viability was seen in Jurkats in the case of delivery with the PTDM in serum 
free conditions, but the other cell types seemed unaffected. In all cases the PTDM in 
complete media out performs the optimized conditions of the other delivery reagents in all 
cell types (serum free conditions).  
4.4. Conclusion 
While many products are being developed for protein delivery, all the commercially 
available options within the class of amphiphilic polymers require optimization, 
performing only in serum free conditions, and do not deliver a large payload into the cells 
of interest. Here, we demonstrate the use of a polymeric peptide mimic (PTDM) that is 
capable of non-covalent protein delivery of GFP into a variety of cell types in complete 
media, outperforming its commercially available counterparts within the same class of 
amphiphilic polymers. In all cell types, the PTDM was able to deliver significantly higher 
amounts of protein into over 80% of cells both in serum free and serum containing 
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conditions. Future work on understanding how amphiphilic polymers interact with their 
cargo protein, as well as protein in the media will enhance development of protein delivery 
into cells. 
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CHAPTER 5 
PROTEIN TRANSDUCTION DOMAIN MIMICS FACILITATE RAPID 
ANTIGEN DELIVERY INTO MONOCYTES 
5.1. Introduction 
Vaccines are currently one of the most effective means of preventing diseases and 
are actively being sought after to train the immune system against innately harder to treat 
diseases such as cancer and HIV as more of a therapeutic approach.233 For protein based 
vaccines, delivering the antigen into the cytosol has considerable challenges due to the 
impermeability of the cell membrane.234 A diversity of approaches has been explored for 
delivering antigens to optimally stimulate a T cells and mount an adaptive immune 
response.235–237  
A sustained T cell response is driven by activation by an antigen presenting cell 
(APC), the bridge between the innate and adaptive immune system. Professional APCs, 
such as macrophages, B cells, and dendritic cells (DCs), promote the activation and 
proliferation of T cells against their major histocompatibility complexes (MHCs) 
displaying a specific antigen.238 When a circulating activated CD8+ T cell recognizes 
material presented in an MHC class I that is foreign, it induces apoptosis in the host cell. 
The distinction between the T cells is important because CD4+ T cells, also known as 
helper T cells, promote an inflammatory environment that encourages the proliferation of 
B cells and subsequent antibody production against the foreign material. CD8+ T cells, 
also known as cytotoxic T lymphocytes (CTLs), function to destroy infected or deformed 
cells within the body.  
Two types of MHCs exist; class I, located on all cell types, interacts with CD8+ T 
cells, while class II, only present on professional antigen presenting cells, is associated 
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with CD4+ T cells. The role of the MHC is to present both foreign and endogenous peptides 
to the immune system and, in the case of APCs, to train T cells against foreign material. In 
APCs, antigen presentation happens via two processes; material that is taken up through 
endosomes is degraded by proteases and fuses with endosomes produced by the ER that 
contain MHC class II, while exogenous material in the cytosol is degraded by proteasomes 
and shuttled to the ER where it is loaded on MHC class I.238 In either case, once the peptide 
is loaded onto the MHC, the complex is then transported to the cell surface, where it can 
be accessed by T cell receptors. A schematic of both processes is presented in Figure 0.1. 
 
Figure 0.1. Processing and presentation of exogenous proteins by antigen presenting 
cells. If the protein is present in the cytosol of the APC, it is processed by a proteasome 
and trafficked to the ER where it is loaded through the MHC class I pathway to prime 
CD8+ T cells. Endosomal uptake of antigen is processed through the class II MHC 
pathway where the protein is degraded within the endosome, which fuses with vesicles 
with the MHC class II and presented to prime CD4+ T cells. Along with presentation 
secondary co-stimulation from the CD4 or CD8 with CD80 and CD86 along with 
cytokine production is required for activation of both types of T cells.  
Cytokines
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Besides antigen recognition by the T cell receptor, T cells require co-stimulation 
and cytokine stimulation to be activated and begin proliferating.239 APCs upregulate the 
expression of costimulatory molecules, such as CD40, CD80, and CD86, and the secretion 
of cytokines, like INF-g, IL-1b, TNF-a, and IL-12p70, when they are triggered by danger 
signals such as agonist like toll-like receptors (TLRs).240  
Almost all vaccines are based on exogenous antigens being endocytosed, 
processed, and presented through the major histocompatibility complex (MHC) class II. 
The antigen loaded MHC II then interacts, along with co-stimulatory molecules, with naïve 
CD4+ T cells which then become activated and begin to divide, promoting an immune 
response against the specific antigen.  
Activation of CD8+ T cells is slightly more complicated because it requires the 
antigen presenting cell to have the foreign material available in the cytosol. While possible, 
this event is rare due to the integrity of the cell membrane and the low number of APCs 
compared with other cell types in the case of viral infection. If the foreign material is 
present in the cytosol, the APC displays the antigen on the MHC I and, along with 
costimulatory molecules (CD86, CD80, and CD40), stimulates CD8+ T cells specific to 
that antigen to divide and become activated. 
In addition to the two classical loading mechanisms, some APCs are able to shuttle 
antigen from endosomes (normally destined for loading on MHC class II molecules) into 
the MHC class I pathway.241 This process is known as cross-presentation and it facilitates 
a CTL response, but is only efficiently performed by dendritic cells (DCs). Along with 
their ubiquitous presence throughout the body and their ability to efficiently activate naïve 
T cells, DCs are a key target for therapeutic vaccines. In an effort to increase DC numbers 
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and immune activation, several targeting strategies have been employed to increase uptake 
in monocytes, a DC precursor.242–246 Since monocytes require differentiation into DCs, one 
strategy that has been explored is the co-formulation of the antigen with endosomal TLR 
agonists.244,247 
Designing an effective MHC I vaccine is the grail of immunotherapy because it 
would allow for the training and expansion of CTLs against a very specific epitope. Recent 
advances in understanding antigen presentation by the innate immune cells and their 
interaction with the adaptive immune system have facilitated a rational approach for design 
and development of vaccine delivery systems. The key elements of an effective vaccine 
are the antigen, or the motif to mount an immune response against, an agonist to stimulate 
the innate immune system, and a delivery system to facilitate the uptake of the cargos into 
the cytosol of APCs for presentation on MHC class I.139  
Nanocarriers are well suited for vaccines because they provide encapsulation of the 
antigen and agonist, as well as allow for delivery into the cytosol of APCs for priming of 
CTLs. Recently, there has been a substantial increase in publications around immunization 
based on synthetic carriers, advancing our understanding of important design criteria to 
elicit a robust immune response with minimal toxicity.139 Many of these nanocarriers are 
able exhibit a strong immune response both in vitro and in vivo, demonstrating their ability 
to prime CTLs against a specific antigen.89,90,234,248,249 
In addition to a variety of lipid and synthetic carriers, cell penetrating peptides 
(CPPs) have been studied for intracellular delivery in vaccine delivery systems.233,250 
Previous reports use either chemical conjugation or a fusion construct with different types 
of antigen cargos, including protein, peptides, DNA, and siRNA.158,251,252 Apart from 
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facilitating intracellular delivery, several examples of CPPs have been reported to prime 
antigen-specific CTLs.252–258 CPPs are attractive because they offer an all-inclusive 
delivery platform that has shown enhanced immune stimulation, though there are still many 
barriers to overcome in this field.233  
Although straightforward, CPPs often require conjugation to their cargo. 
Previously, we have shown non-covalent delivery of functional cargos into the cytosol and 
nucleus of T cells using synthetic CPPs, also termed protein transduction domain mimics 
(PTDMs).134,259 In addition to T cells, we have shown uptake into a variety of other cell 
types (unpublished), suggesting that the PTDM might provide a facile solution to 
delivering antigen into the cytosol of APCs. Herein, we describe the optimization of 
delivering the model antigen SIINFEKL into monocytes in whole blood, as well as 
immature dendritic cells in vitro for presentation on the MHC class I using an amphiphilic 
block copolymer. Additionally, the differentiation of the monocytes and production of 
inflammatory cytokines was explored when the antigen was delivered with the endosomal 
TLR9 agonist CpG. Understanding the efficacy of these PTD mimics provides an important 
foundation for future applications of PTD technology in the field of peptide-based vaccines 
towards intracellular pathogens and immunomodulation of disease. 
5.2. Materials and Methods 
5.2.1. PTDM Synthesis and Characterization 
Monomers and polymers were synthesized according to previously established 
procedures as reported in 2.2.3.229,260 Briefly, to create the monomer, the exo Diels-Alder 
adduct of maleic anhydride and furan was ring-opened with the desired alcohol to introduce 
the first substituent. A second alcohol was then added using EDC coupling. The desired 
polymers were obtained by ring-opening metathesis polymerization using Grubb’s third 
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generation catalyst in dichloromethane and end terminated with either ethyl vinyl ether or 
an activated ester, which was then reacted with FITC. After polymerization, the Boc groups 
protecting the guanidinium groups were removed with a 1:1 solution of trifluoroacetic acid 
and dichloromethane. The final products were purified by dialysis against RO water and 
recovered by lyophilization. 
5.2.2. Cell Preparation 
5.2.2.1. Whole Blood 
Whole human blood was obtained from healthy volunteers under signed consent in 
BD Vacutainers containing hirudin. In all cases, blood was used within 10 minutes of the 
tapping from the donor. The blood was distributed into Eppendorf tubes containing 
preassembled polymer preparations in RPMI 1640 with no supplements and incubated up 
to 1 hour at 37˚C on rotation (60 RPM). In general, 400 µL of blood was combined with 
100 µL of polymer complex prepared in RPMI 1640 for a final volume of 500 µL.  
In the case of plasma free whole blood delivery, whole blood was centrifuged at 
200 g immediately upon receipt, plasma was removed, and cells were washed with RPMI 
1640 three times before suspension to the original volume with RPMI 1640. The washed 
blood was then allocated to the polymer preparations and incubated on rotation (60 RPM) 
for 1 hour at 37˚C. 
5.2.2.2. Cell Lines 
Jurkat T cells (clone E6-1, ATCC TIB-152) and THP-1 cells (ATCC TIB-202), 
were grown in RPMI 1640 supplemented with 10% (v/v) FBS, L-glutamine, Non Essential 
Amino Acids (NEAA), Na-pyruvate, HEPES, 100 U/mL penicillin, and 100 U/mL 
streptomycin at 37˚C, 5% CO2 and were passaged 24 hours before treatment. Polymers 
were mixed with cargo and allowed to complex for 30 minutes. Jurkats were harvested and 
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suspended in fresh complete media and placed into a 12 well plate at 4X105 cells/mL. 
Polymer-cargo complexes were applied drop-wise to each well. Cells were treated for 4 
hours, then washed 3 times with 20 U/mL heparin in PBS before being suspended in 0.2% 
BSA in PBS FACS buffer and stained with 7-AAD for analysis by flow cytometry. 
To establish immature dendritic cells, previously established protocols were 
used.261 Briefly, THP-1s were incubated with 100 ng/mL IL-4 and 100 ng/mL GM-CSF 
for 5 days, with the media and cytokines being replaced every 2 days. Differentiation was 
confirmed by increased expression in CD11c and HLA-DR as well as a morphological 
change. 
5.2.2.3. Bone Marrow Derived Dendritic Cells 
Immature dendritic cells were differentiated from murine bone marrow according 
to established protocols.262 Discarded legs from C57BL/6 mice were graciously donated 
by the Pobezinsky lab. Bones were cleaned with ethanol and cells were harvested using a 
28-gauge syringe. RBCs were lysed using BioLegend® lysis buffer and cells were plated 
at a density of 2X105 cells/mL in complete RPMI (listed under cell lines) with the addition 
of 20 ng/mL recombinant mouse GM-CSF. Cells were cultured for 6 days with the addition 
of 10 mL fresh media and cytokines on day 3. Non-adherent and loosely adherent cells 
were harvested on day 6 and cells were pelleted, counted, and plated at a density of 2X106 
cells/mL. 
5.2.3. Flow Cytometry 
After incubation, cells were pelleted at 200 g for 5 minutes and the supernatant was 
removed. Red blood cells were lysed in using BD Pharm lysis buffer and subsequently 
washed with 1% FBS in PBS twice before staining with antibodies. Unspecific binding 
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was blocked for 10 minutes using human or mouse IgG respectively. Antibody surface 
staining was performed using antibodies for Human CD14-APC, CD40-PE, CD80-AF488, 
CD86-BV711, CD209-APC, HLA-DR-APC-Cy7, or Mouse CD11c-AF488, CD86-
AF647, HLA-DR, H-2Kb-PE as indicated by manufacturer (BD® or BioLegend®). 
Briefly, cells were transferred to a 96 well plate where the respective antibodies 
were added accordingly. Samples were incubated for 30 minutes on ice after which samples 
were washed 3 times with 1% FBS in PBS before analysis by flow cytometry.  
Whole blood samples were collected on a BD® Accuri C6™ flow cytometer with 
two lasers (488 and 640nm) with three channels on the blue laser (533/30, 585/40, and 670 
LP) and one channel on the red laser (675/25). For whole blood experiments, 100,000 
single events were collected for each sample using a minimum FSC-H cutoff of 1,200,000. 
THP-1 monocytes, immature dendritic cells, and bone marrow derived dendritic 
cells were analyzed using a BD LSR Fortessa 20X flow cytometer with five lasers and 18 
channels. For both cell lines, 10,000 single events were collected for each sample, while 
for the bone marrow derived cells, a minimum of 50,000 single cell events were collected. 
Only cells negative for 7-AAD were assessed for either uptake or presentation of markers. 
Multi-color flow cytometric analysis spectral overlap was corrected by appropriate 
compensation and analyzed using FlowJo™ 10.2 by Tree Star®. 
5.2.4. Cytokine Profiling 
After one hour of incubation with treatment as reported under cell preparation and 
culture, cells were pelleted at 400 g for 2 minutes and supernatant was removed. Cells were 
washed 3 times with RPMI supplemented with 100 U/mL pen/strep, and plated into a 96 
well round bottom plate where they were incubated at 37˚C and 5% CO2 for 24 hours. After 
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incubation, cells were pelleted at 5000g and supernatant was transferred to a fresh 96 well 
plate and frozen at -80˚C until testing. Measurements of IL-6 were performed immediately 
after thawing frozen supernatant using ELISA, R&D Systems. Cytokine production was 
detected using the inflammatory cytometric bead array Legendplex™ from BioLegend® 
which included IL-1b, IFN-a, IFN-g, TNF-a, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-
17A, IL-18, IL-23, and IL-33. 
5.2.5. Statistical Analysis 
All flow cytometry experiments were repeated in at least biological triplicate. Data 
sets were expressed as means ± SEM Statistical significance of differences was determined 
by one or two way ANOVA followed by a Bonferroni post hoc test. Differences were 
considered statistically significant for p<0.05. Statistical analysis was performed using 
Prism™ 5.0a by Graphpad® Software. 
5.3. Results and Discussion 
5.3.1. MePh10-b-dG5-FITC Treatment of Whole Blood 
To understand the interaction of the PTDM with cells in whole blood, FITC labeled 
MePh10-b-dG5 (Figure 0.2A) was added to freshly collected human whole blood for 1 hour 
at a final concentration of 2.8 µM. After lysis of red blood cells (RBCs) and staining with 
anti-CD14 and anti-CD15, polymer showed low association with granulocytes (CD15+) 
and lymphocytes (morphological gate) as seen in Figure 0.2C, while the MFI and uptake 
in monocytes (CD14+) was statistically higher than the blank and the other two cell 
populations. Viability, determined by staining with 7-AAD, was not statistically different 
from the blank with 95.8 ± 1.6 % live cells. 
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Figure 0.2. Delivery of 2.8 µM FITC labeled polymer (A) into whole blood for 1 hour. 
Cells were gated morphologically (B) and monocytes were confirmed with CD14 
staining, while granulocytes were confirmed with CD15 staining within the respective 
morphological gate. Uptake within each of the morphological gates was determined 
by a shift in FITC intensity from the blank (C). The mean±SEM of the median 
fluorescence intensity (MFI) on the top and percent positive cells on the bottom of 4 
separate donors is shown (D). 
Specific uptake by the monocyte population is interesting but slightly unsuprising 
due to their phagocytotic nature. Since we have previously shown delivery into a variety 
of cell types, the logical next step was to deliver a cargo complexed with the polymer. 
SIINFEKL peptide, the MHC class I specific sequence of ovalbumin (OVA) was chosen 
as a model antigen.  
5.3.2. Optimization of Delivery into Jurkat T Cells 
In order to determine the most effective concentration of peptide and the subsequent 
ratio of peptide to polymer (MePh10-b-dG5), a survey of peptide concentrations (0.1, 0.5, 
1, and 5 µM) crossed with protein to polymer ratios (1:5, 1:10, 1:15, and 1:20) was 
investigated in Jurkats. In this case, SIINFEKL was fluorescently labeled with FAM to 
showcase ability of cargo delivery. Peptide-polymer complexes were allowed to form for 
30 minutes prior to addition to the cells in complete RPMI. Cells were treated for 4 hours, 
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after which they were washed three times with heparin to remove excess peptide adhered 
to the outside of the cell. Uptake and viability (7-AAD staining) was assessed using flow 
cytometry and is shown in Figure 0.3. The trend between peptide to polymer ratios was 
consistent across all peptide concentrations, with a ratio of 1:10 performing similarly to 
1:20 indicating that higher ratios of polymer would not necessarily enhance delivery.  
 
Figure 0.3. A concentration survey for the delivery of SIINFEKL into Jurkat T cells 
at varying ratios of peptide to polymer. Cells were treated with the complexes for 4 
hours, washed three times with heparin, and analyzed by flow cytometry for their 
ability to deliver SIINFEKL. Viability (left) was determined using 7-AAD, MFI 
(middle) indicates the amount of peptide delivered to the cells, and % positive cells 
(right) indicates the population of cells that were delivered into. Experiments were 
repeated in triplicate and the mean and SEM are displayed.  
5.3.3. Time Survey of Peptide Delivery into Whole Blood 
The specificity of uptake of the polymer-antigen complex by monocytes was tested 
in whole blood. 1 µM FAM labeled SIIFNEKL was delivered into whole blood using 
MePh10-b-dG5 at a ratio of 1:10, for 15, 30, 45, or 60 minutes to investigate the kinetics of 
uptake. MFI and uptake were not statistically different regardless of the incubation time. 
Additionally, complex uptake was compared with free SIINFEKL-FAM allowed to 
incubate with whole blood for 60 minutes. High association with the monocytes is seen 
within the first 15 minutes (Figure 0.4) compared with lymphocytes and granulocytes, 
consistent with the previous observations. The free peptide is not readily taken up in large 
amounts by any of the white blood cells.  
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Figure 0.4. Delivery of fluorescently labeled SIINFEKL complexed with PTDM at a 
ratio of 1:10 into whole blood for 15, 30, 45, and 60 minutes. Whole blood was also 
treated with soluble SIINFEKL for 60 minutes as a comparison. Cell types were gated 
on morphologically then with CD14 and CD15 to determine true monocytes and 
macrophages, respectively. The mean and SEM of 4 separate donors is displayed for 
the MFI (left) and % positive (MFI) cells within the established gates.  
Rapid specific uptake of the fluorescently labeled antigen in monocytes showcases 
the ability of the PTDM to significantly enhance uptake of the model cargo. The relatively 
low association and uptake seen with the free peptide suggests that some property of the 
polymer enhances association and uptake with monocytes. Since the PTDM has been 
shown to deliver into multiple cell types, increased concentrations were investigated for 
induced uptake in the granulocyte and lymphocyte populations.  
5.3.4. Concentration Survey of Peptide Delivery into Whole Blood 
FAM labeled SIINFEKL was delivered into whole blood using MePh10-b-dG5 at a 
ratio of 1:10 at increasing concentrations of peptide (0.25, 0.5, 1, and 2 µM). The MFI and 
% positive cells are shown in Figure 0.5A, suggesting that 1 µM of peptide was optimal 
because almost 100% of the cells show uptake and the MFI is significantly distinguishable 
from the untreated sample. Increasing the concentration to 2 µM appears to yield a higher 
MFI, but also requires more polymer. High uptake was exhibited almost exclusively in the 
monocytes labeled with CD14 and not significantly in the lymphocytes and granulocytes, 
consistent with the previous observations.  
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Figure 0.5. (A)Delivery of fluorescently labeled SIINFEKL complexed with PTDM at 
a ratio of 1:10 into whole blood at peptide concentrations of 0.25, 0.5, 1, and 2 µM of 
peptide. Cell types were gated on morphologically then with CD14 and CD15 to 
determine true monocytes and macrophages, respectively. (B) IL-6 production was 
determined for unlabeled SIINFEKL delivered under the same conditions 24 hours 
after treatment in comparison to the positive control Resiquimod, a TLR7 agonist. 
The mean± SEM of 4 separate donors is displayed. 
Even at high concentrations, uptake is promoted in only the monocyte population, 
confirming that the polymer promotes specific interaction with these phagocytic cells. 
Although uptake is promoted, monocytes themselves do not serve a specific function in 
terms of promoting a specific immune response. Monocytes can differentiate into two types 
professional antigen presenting cells, macrophages and dendritic cells, upon stimulation 
and activation.238 Usually, the differentiation into dendritic cells can be marked by a change 
in cell specific surface marker expression such as upregulation of MHC class I and DC-
sign (CD209) as well as in inflammatory cytokine production.261,263  
To further investigate the ability of the polymer-peptide complexes to cause an 
inflammatory cytokine environment, whole blood was treated with the same conditions as 
in the concentration survey (0.25, 0.5, 1, and 2 µM peptide at a 1:10 peptide to polymer 
ratio) and the production of IL-6 was probed 24 hours after the treatment (Figure 0.5B). 
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The whole blood was added to the polymer complexes for 1 hour on rotation, after which 
the plasma was removed and the cells were washed three times with non-supplemented 
RPMI. The cells were incubated at 37˚C for an additional 24 hours and the supernatant was 
collected to perform an IL-6 ELISA. No significant IL-6 production detected with any of 
the treatments, except the positive control Resiquimod, a TLR7 agonist. The results 
indicate the polymers alone and in complex with SIINFEKL do not produce pro-
inflammatory signals in blood, even at high concentrations. Since the complexes show high 
uptake but are not inflammatory, they most likely do not cause the monocytes to 
differentiate. The differentiation and activation of the monocytes in whole blood can be 
induced by delivering an agonist in addition to the antigen. 
5.3.5. SIINFEKL Delivery with Amphiphilic Peptides 
Since high uptake in monocytes was demonstrated using MePh10-b-dG5, similar 
peptides were tested to compare their ability to non-covalently associate SIINFEKL and 
facilitate uptake in whole blood. Two peptides were chosen, R9 and Pep-1, for their 
cationic nature and previously shown ability to translocate cells to deliver biomolecular 
cargo.35,119 As before, the peptides were complexed for 30 minutes in the presence of 
SIINFEKL. Since delivery in the presence of protein inhibits the ability of many carriers 
to deliver into cells, the plasma was removed from the blood by washing with RPMI three 
times and suspending the cells back to the original collected volume. The plasma free blood 
was then added to the complexes and put on rotation for 1 hour at 37˚C after which the 
RBCs were lysed and cells were stained with anti-CD14.  
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Figure 0.6. Delivery of fluorescently labeled SIINFEKL into whole blood using the 
well known cell penetrating peptides pep-1 and R9 in comparison with MePh10-b-dG5 
after 1 hour incubation. Cell types were gated on morphologically then with CD14 
and CD15 to determine true monocytes and macrophages, respectively. The mean 
and SEM of 6 separate donors is displayed for the MFI (left) and % positive (MFI) 
cells within the established gates. 
Analysis by flow cytometry, shown in Figure 0.6, indicated negligible delivery 
when the SIINFEKL was introduced by itself or in the presence of the tested peptides. In 
contrast, the MePh10-b-dG5 facilitated uptake in the monocytes, clarifying that plasma 
proteins are not directly responsible for the uptake of the polymer-antigen complex in terms 
of aggregation or opsonization. 
5.3.6. Optimization of CpG and OVA Protein Ratio to Polymer  
To introduce a controlled cytokine response, CpG, a TLR9 nucleotide agonist was 
chosen for co-delivery with the chosen agonist. Since the polymers studied here have never 
been tested for co-delivery, optimization was required to determine the optimal ratio of 
polymer to CpG and the protein OVA, as well as any requirements about complex 
formation. In this case, the whole protein was chosen over the peptide antigen due to the 
compatibility of fluorophores that were readily available for each of the cargos. 
Additionally, a second polymer, dPh10-b-dG5, was added to briefly determine if polymer 
architecture would affect association and uptake of the two different cargos.  
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The delivery of CpG-FITC and OVA-AF647 were optimized separately in Jurkats 
through determining the optimal N/P ratio for 100 nM CpG and protein/polymer ratio for 
50 nM OVA. Cargos were complexed with two polymers (MePh10-b-dG5 and dPh10-b-
dG5) at increasing ratios for 30 minutes in PBS. N/P ratios of 1:1, 2:1, 4:1 and 8:1 (Figure 
0.7A and B) and protein-polymer ratios of 1:5, 1:10, 1:20, and 1:40 (Figure 0.7C and D) 
were assessed for CpG and OVA, respectively. Complexes were added drop-wise to 
Jurkats and incubated at 37˚C for 4 hours after which they were washed with heparin to 
remove any residual cargo stuck to the outside of the membrane and uptake was assessed 
by flow cytometry. CpG-FITC delivery peaked at a ratio of 4:1 for both polymers, while 
OVA delivery was best at a ratio of 1:40 for the MePh10-b-dG5 compared with 1:20 being 
sufficient for the dPh10-b-dG5. 
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Figure 0.7. Optimization for delivery of CpG-FITC and Ovalbumin (OVA-AF647) in 
Jurkat T cells to determine the optimal ratio of cargo to polymer. Two polymers were 
assessed for their ability to deliver both cargos. Polymers were complexed with 100 
nM CpG at N:P ratios of 1:1, 2:1, 4:1, and 8:1 for 30 minutes and then applied to cells 
in complete media for 4 hours. The percentage of cells positive for CpG (A) and MFI 
(B) were determined by flow cytometry. 50 nM OVA was complexed with the 
polymers at ratios of 1:5, 1:10, 1:20, and 1:40 prior to 4 hours of delivery. Similarly, 
percent positive (C) and the MFI (D) were assessed via flow cytometry. The mean and 
SEM are displayed for three independent experiments.  
The ability of the polymers to deliver the CpG and OVA into the same cell was 
tested for the necessity to complex the cargos with the polymers separately (postmix) or 
together with the polymer at the same time (premix). In the case of postmix, the cargos 
were mixed with either MePh10-b-dG5 or dPh10-b-dG5 and allowed to complex before 
simultaneous addition of the antigen complex and agonist complex to the cells, while in 
the premix version, all three substituents were added and allowed to complex together 
before addition to the cells. The fluorescence intensity of both cargos was assessed by flow 
cytometry after 4 hours incubation and subsequent heparin washing (Figure 0.8). 
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Figure 0.8. Optimization of co-delivery of 100 nM CpG-FITC and 50 µM OVA-AF647 
into Jurkat T cells. MePh10-b-dG5 or dPh10-b-dG5 was complexed with CpG and OVA 
either individually (postmix) or all together (premix) for 30 minutes before treatment 
of cells in complete media. The MFI for CpG (A) and OVA (C) were assessed 
individually on the population as a whole. The percentage of cells positive for both 
cargo types (B) was assessed along with Viability (D) using 7-AAD after 4 hours by 
flow cytometry. The mean and SEM are shown for 3 independent experiments. 
For the single polymer samples (MePh+CpG+OVA and dPh+CpG+OVA), no 
statistical difference was seen between the set that was mixed individually (PTDM with 
OVA separate from PTDM with CpG) and those that were mixed together (PTDM with 
OVA and CPG). Additionally, both polymers appeared to deliver with the same efficacy. 
When both polymers were used together to complex cargo, the premix strategy was far 
superior. Consequently, premixing everything together was adopted and only MePh10-b-
dG5 was continued with for all subsequent co-delivery experiments. 
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5.3.7. Co-Delivery of CpG and OVA in Whole Blood 
After optimization, the polymer-antigen-agonist complex was delivered into whole 
blood to see if the addition of the agonist effected the association with monocytes and if 
the complex promoted differentiation or activation. CpG and OVA were premixed with the 
polymers at the previously determined ratios of N/P = 4:1 for the CpG and 1:20 or 1:40 for 
the respective polymers with increasing concentrations of CpG. Whole blood was treated 
with the various complexes for 60 minutes to investigate uptake. Based on MFI, Figure 
0.9, the polymers cause significantly higher uptake in the morphological granulocytes and 
monocytes gates at the higher concentrations. It was apparent with the loss of cells within 
the typical monocyte morphological gate that the assay was inconclusive. The cells positive 
for both OVA and CpG lie within the lower side of the granulocyte population. Further 
evidence to support the idea of monocyte differentiation into macrophages, and the 
subsequent shift up in side scatter is required. To follow up, delivery into a single culture 
of monocytes was investigated.  
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Figure 0.9. Co-delivery of CpG-FITC and OVA-AF647 complexed with MePh10-b-
dG5 into whole blood. Increasing concentrations of CpG were used (50, 100, and 200 
nM) along with 50 nM OVA protein. Uptake into the morphological granulocyte, 
lymphocyte, and monocyte gates are shown as a function of CpG MFI (top), OVA 
MFI (middle), and percentage of cells positive for both cargos (bottom).  
To quickly check for upregulation of differentiation marker DC-sign, the complex 
was compared with treatment of whole blood with IL-4 and GM-CSF, cytokines that can 
be used to induce differentiation into dendritic cells. After 1 hour of treatment, followed 
by washing and a 24 hour incubation, the cells treated with the polymer-antigen-agonist 
complex showed a slight increase in upregulation of DC-sign, as seen in Figure 0.10, but 
the increase was not substantial in relation to the cytokine treated cells. It is possible that 
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at a longer time point higher upregulation of this marker would occur. Alternatively, the 
amount of CpG added might be too low to cause significant upregulation of DC-sign.  
 
Figure 0.10. Co-delivery of SIINFEKL and CpG with MePh10-b-dG5 compared with 
cytokine treatment to differentiate monocytes into dendritic cells. Whole blood was 
treated for 1 hour, then washed and incubated for an additional 24 hours to look at 
the upregulation of DC-sign (CD209) within the monocyte (CD14) population. The 
PBS negative control (left) and cytokine positive control (middle) compared with the 
polymer-antigen-agonist complexes.  
5.3.8. Delivery into THP-1 Monocytes 
A multi-analyte inflammatory cytokine panel was used to understand the immune 
response for the addition of CpG into the complexes. Supernatants from whole blood at 24 
hours after a 60 minute treatment with the polymer-SIINFEKL-CpG complexes were tested 
using a standardized inflammation panel including IL-1b, IFN-a, IFN-g, TNF-a, MCP-1, 
IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33. A statistical summary of 
cytokine production is summarized in Table 0.1. When CpG was delivered by itself, it 
caused an increase in IL-1b, IFN-a IFN-g, TNF-a, IL-6, MCP-1, and IL-12p70, which are 
all indicative of a pro-inflammatory response directed by the differentiation and activation 
of professional antigen presenting cells. In general, cytokine response with the addition of 
SIINFEKL did not change this profile suggesting that the two cargos can be delivered 
together to perform their individual functions. Additionally, the production of IL-12p70 is 
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especially interesting because it indicates the active heterodimer is being produced by 
APCs to stimulate T cells. In combination with INF-g and TNF-a, IL-12p70 enhances the 
cytotoxic activity of CTLs suggesting that the delivery of CpG and SIINFEKL with the 
PTDM may facilitate an enhanced immune response.  
Table 0.1. Inflammatory cytokine panel for the co-delivery of SIINFEKL and CpG 
using MePh10-b-dG5 into whole blood. Supernatant was collected 24 hours after 
treatment and analyzed using a cytometric bead array. Statistical difference was 
determined from the untreated sample from 3 independent donors (*p<0.05, 
**p<0.005, ***p<0.0005) 
 
 
5.3.8.1. Cytokine Response to Co-Delivery of SIINFEKL and CpG  
FAM labeled SIINFEKL or OVA labeled with FITC were delivered respectively 
using MePh10-b-dG5 into THP-1s, a human monocyte cell line. 1 µM of each cargo was 
complexed respectively with the polymer at a 1:10 protein/peptide to polymer ratio for 30 
minutes before application to cells in complete media. The lowered ratio used in this 
experiment was an attempt to lower the amount of polymer required and therefore mitigate 
cytotoxicity. Cells were treated for 4 hours, then washed 3 times with 20 U/mL heparin 
prior to analysis by flow cytometry. The MePh10-b-dG5 facilitated delivery of both cargos 
into the THP-1 monocytes, shown in Figure 0.1A and B, confirming its ability to deliver 
into this cell type. Viability, determined by 7-AAD staining, remained similar to untreated 
cells above 95% in relation to the untreated blank.  
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Figure 0.11. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) into THP-1 cells 
using MePh10-b-dG5. Cells were treated for 4 hours, then washed 3 times with heparin 
(20 U/mL) and assessed for uptake of the cargos by flow cytometry. Upregulation of 
activation surface markers (C) on THP-1s 24 hours after delivery of polymer-antigen-
agonist complexes. Cells were treated for 4 hours, then washed one time with media 
and allowed to incubate for 20 more hours. LPS was used as a positive control. Cells 
were stained with antibodies for DC-sign (CD209), HLA-DR (MHC II), CD86, CD80, 
and CD40. The mean ± SEM are shown from 3 independent experiments. 
To investigate the differentiation and activation of the monocytes by a polymer-
antigen-agonist complex, the 10 µM MePh10-b-dG5 was complexed with 1 µM unlabeled 
SIINFEKL or OVA along with 1 µM CpG, a TLR9 agonist, for 30 minutes and cells were 
treated for four hours. The cells were centrifuged and washed one time with PBS before 
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being suspended in complete media for an additional 20 hours, after which the supernatant 
was collected for ELISA and the cells were stained with antibodies for CD11c (a DC 
marker), CD40, CD80, CD86, and MHC class II (HLA-DR). Minor upregulation of the 
CD40, CD80, and CD86 could be seen in samples treated with the polymer-antigen-agonist 
complex (Figure 0.11C). 
Although a multi-analyte cytometric bead array was used to determine cytokine 
production during the 20 hour incubation after treatment, no statistical increase was seen 
in any of the analytes, not even when treated with LPS, the positive control. These results 
may be due to too low cytokine concentration in all of the samples, requiring the 
experiment to be done in a higher density of cells with a lower volume, over a variety of 
time points. It is also possible that the monocytes were not stimulated enough by the 
concentrations of polymer-antigen-agonist and that higher concentrations of the complexes 
would lead to more definitive results.  
5.3.9. Delivery into Immature Dendritic Cells 
Delivery into immature dendritic cells (iDCs) was also investigated in partially 
differentiated antigen presenting cells. iDCs were stimulated for 6 days to cause 
upregulation of MHC class II (HLA-DR) and DC-sign, indicating their ability to be primed 
for T cell stimulation. Similar to the THP-1s, 1 µM fluorescently labeled SIINFEKL or 
OVA complexed with MePh10-b-dG5 at a ratio of 1:10 were delivered into the iDCs 
derived from THP-1s (Figure 0.12A and B), showing significant uptake of the peptide 
compared with the free soluble counterpart. More variation of OVA protein uptake was 
seen than with the Thp1s, possibly due to inconsistent differentiation between the three 
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trials. The high SIINFEKL uptake in these cells indicate that the PTDM facilitates the 
delivery of antigen into iDCs.  
 
Figure 0.12. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-b-
dG5 into immature dendritic cells derived from the THP-1 cell line. Cells were treated 
for 4 hours, then washed 3 times with heparin (20 U/mL) and assessed for uptake of 
the cargos by flow cytometry. The mean and SEM are shown as a result of 3 
independent experiments. Upregulation of activation surface markers (C) on iDCs 24 
hours after delivery of polymer-antigen-agonist complexes. Cells were treated for 4 
hours, then washed one time with media and allowed to incubate for 20 more hours. 
LPS was used as a positive control. Cells were stained with antibodies for DC-sign, 
MHC II, CD86, CD80, and CD40. 
Co-delivery of the antigen and agonist was performed to probe upregulation of co-
stimulatory molecules, as well as production of inflammatory cytokines. Surface marker 
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staining, Figure 0.12C, revealed a slight upregulation of CD80, CD86, and CD40 in the 
samples that received the polymer-antigen-agonist complex. Although the upregulation 
was not substantial, it is possible that higher concentrations of CpG or for longer are 
required to produce significant upregulation of surface markers and production of 
inflammatory cytokines.  
5.3.10. Delivery into Bone Marrow Derive Dendritic Cells 
Perhaps the most conventional and telling way to scrutinize whether the PTDM-
antigen-agonist complex will enhance vaccination through delivery of a specific peptide is 
to probe immature dendritic cells that would subsequently be able to stimulate T cells. In 
this case, complexes are delivered into mouse bone marrow derived dendritic cells 
(BMDCs) that would internally process the antigen via the MHC class I and class II 
pathways and present the antigen along with respective costimulatory molecules. Since we 
have chosen a peptide that is specifically presented in MHC class I, we can probe for the 
display, as well as the upregulation of CD86, a costimulatory molecule.  
To test SIINFEKL delivery and presentation for T cell activation, bone marrow 
derived dendritic cells were differentiated from C57BL/6 mouse bone marrow for 6 days 
in the presence of 20 ng/mL mouse GM-CSF. After 6 days, cells were harvested and treated 
with 1 µM fluorescently labeled SIINFEKL or OVA both free and in complex with 
MePh10-b-dG5 ratio of 1:10 for 4 hours. Substantial uptake was seen in the presence of 
polymers while significantly less uptake was seen for the free antigen in both cases (Figure 
0.13A and B).  
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Figure 0.13. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-b-
dG5 into immature dendritic cells derived from C57BL/6 mouse bone marrow. Cells 
were treated for 4 hours, then washed 3 times with heparin (20 U/mL) and assessed 
for uptake of the cargos by flow cytometry. Upregulation of activation markers (C) 
on BMDCs 24 hours after delivery of polymer-antigen-agonist complexes. Cells were 
treated for 4 hours, then washed one time with media and allowed to incubate for 20 
more hours. LPS was used as a positive control. Cells were stained with antibodies 
for MHC II, CD11c, CD86, and H-2Kb (presentation of SIINFEKL in MHC class I). 
The mean and SEM are shown for BMDCs derived from 3 mice. 
In addition to delivery of fluorescently labeled cargo, both OVA and SIINFEKL 
were delivered in combination with 1 µM CpG to investigate presentation of SIINFEKL 
in the MHC class I along with upregulation of CD86 and the production of inflammatory 
cytokines indicating the ability of these DCs to activate T cells. After differentiation, cells 
were treated for 4 hours with the polymer-antigen-agonist complexes, after which cells 
were washed 1 time with PBS and suspended in fresh media for 20 hours. To determine 
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upregulation, cells were stained with antibodies for CD11c and MHC class II to indicate 
DCs, as well as CD86, and H-2Kb and results are shown in Figure 0.13C. 
Since SIINFEKL can be extracellularly loaded into the MHC class I by diffusion,238 
some display was expected just by adding the soluble peptide to the cells. The presentation 
of SIINFEKL on the MHC class I was observed to be significantly higher for samples 
treated with polymer-SIINFEKL-CpG compared with just soluble SIINFEKL alone or 
when the polymer is used to deliver only the peptide. The high level of the antigen in the 
MHC class I confirms that the complexes deliver and facilitate presentation for T cell 
stimulation. Unexpectedly, the costimulatory molecule CD86 was not significantly 
upregulated in any of the polymer treated samples, though the time point or concentration 
of chosen agonist may directly affect display of this marker.  
Additionally, samples treated with polymer-OVA-CpG did not result in any display 
of SIINFEKL on the MHC class I as determined by staining with the H-2Kb. Lack of 
display for OVA treated samples may be due to slow and inconsistent processing of the 
OVA protein intracellularly. Higher presentation may be observed at a different time point 
or at higher concentrations of OVA. While delivering a complete protein is conceptually 
interesting, the ability to deliver a specific sequence or set of sequences allows more control 
over what the specific immune response will be against. 
5.4. Conclusion 
In summary, we have shown specific delivery of SIINFEKL into monocytes in 
whole blood is a rapid process, happening in under 15 minutes without concentration 
dependence. The complex of the polymer with antigen does not appear to be immunogenic 
even at increased concentrations lending the ability to tune the immunogenicity using the 
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TLR9 agonist CpG. Additionally, the PTDM described here is superior to directing 
monocyte uptake of the non-covalently complexed cargo when compared with amphiphilic 
peptide counterparts.  
When the SIINFEKL was delivered in combination with CpG in whole blood, a pro 
dendritic cell cytokine environment was observed suggesting the differentiation of the 
monocytes into professional APCs. The differentiation was not easily substantiated in the 
mixed cell culture, so THP-1s were cultured with the polymer-antigen-agonist complexes 
to investigate maturation of the monocytes. Although no inflammatory cytokines were 
produced from the monocyte culture, there was a slight upregulation of CD40, CD80, and 
CD86 suggesting that further time points as well as concentrations may elucidate whether 
the monocytes differentiate. Similar results were seen in immature dendritic cells 
differentiated from the THP-1s showing that uptake is possible in both cell types. 
Delivery of both peptide and protein antigen into BMDCs showed high uptake. 
High levels of presentation of the SIINFEKL in the MHC class I was observed in samples 
treated with the polymer-SIINFEKL-CpG complexes indicating increased presentation. 
Although no co-stimulatory molecules were detected, further investigation into the 
concentration and timing of the complexes remains to be explored.  
The enhanced display of SIINFEKL in MHC class I is a promising step toward 
using PTDMs to stimulate a specific immune response using antigen presenting cells. This 
study opens the door for further investigation of using amphiphilic polymers to promote 
antigen and agonist delivery into antigen presenting cells for training and eliciting a 
specified activation and response from CTLs. Future exploration is focused on the 
expansion of T cells against the antigen and agonist treated BMDCs as well as 
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understanding how concentration of the antigen and agonist are reflected in their ability to 
promote a sustained T cell response.  
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PERSPECTIVES AND FUTURE WORK 
The exploration of how PTDM structure affects the internalization of cargo is just 
at its beginning. Herein, we have motivated how small changes in length and 
hydrophobicity can greatly influence the ability of protein delivery using non-covalent 
interactions. Current work understanding how the polymers interact with their cargos is 
underway and future exploration regarding how the structure of the polymer influences 
self-assembly both in the presence and absence of serum would benefit the design of the 
polymer system. The assembly properties may influence interaction with the cell 
membrane, changing the ability of the polymers to permeate into the cytosol with their 
cargo. To accomplish this, further experiments using light scattering should be combined 
with ion exchange chromatography and cryo-TEM to fully understand self-assembly and 
assembly with cargos.  
In addition to fluorescence, proteins that have functional biological activity would 
further bolster claims of cytosolic delivery. To date, Cre recombinase is the only enzymatic 
protein that has been shown to have function in the cell.134 While it is encouraging that 
delivered proteins retain their function, since we do not totally understand the polymer 
protein interaction, it is hard to know if the PTDMs affect the function of the protein. To 
explore this, a survey of enzymes should be delivered to correlate binding affinity with 
protein function. Not only would a survey prove that the PTDMs are compatible with a 
variety of proteins, it would also facilitate understanding of protein-polymer dynamics.  
The CRISPR/Cas9 system is of particular interest because it would allow for gene 
editing. Delivery of the ribonuclear protein in conjunction with the cRNA would enable a 
simple, fast way to edit genomes of cells. Exploration of this protein cargo is already 
underway with several research groups, suggesting that it can be achieved using the right 
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protein carrier. Labeled versions of the protein and cRNA can be used to assess delivery 
conditions, as well as what architecture polymer best delivers the cargo into cell. Enzymatic 
activity can be easily tested using an T7E1 assay to determine gene knockout efficiency. 
Alternatively, several designer cell lines exist that allow for knock out or knock in of 
fluorescent genes. The ability to knock out a gene using the CRISPR/Cas9 system would 
prove preserved enzyme functionality, as well as support the ability of the cargo to reach 
the nucleus via delivery into the cytosol.  
With a better understanding of how polymer structure can be tailored to different 
types of cargo, PTDMs can be used in various capacities to probe molecular pathways in 
immune cells through the delivery of proteins and antibodies. In terms of vaccines, we have 
established the ability to deliver both an antigen and an agonist into both monocytes as well 
as immature dendritic cells and see enhanced display of the antigen in the MHC class I at 
a prolonged time point. The correct timing and concentrations of agonist to boost 
costimulatory molecules and cytokines remains largely unexplored. Evaluation of the 
effect of antigen and agonist concentrations on surface marker and cytokine expression 
over a series of time points would provide insight into how much of these cargos are 
required to facilitate an immune response. APCs derived from mouse bone marrow serve 
as the best ex vivo example since comparable cell lines cannot express some of the classical 
cytokines or markers.  
Further optimization in terms of antigen presentation on APCs and T cell priming 
would elucidate the ability of the PTDMs to help mount a specific T cell response against 
the chosen antigen. Specifically, T cell proliferation against the delivered antigen, as well 
as cytotoxicity of those trained T cells would provide evidence of enhanced vaccines. To 
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achieve this, DCs differentiated from C57BL/6 bone marrow should be treated with 
optimized antigen-agonist-polymer complexes as determined by production of high 
cytokine levels of TNF-a and IFN-g along with upregulation of CD80 and CD86. After the 
DCs are pulsed with the complex, CD8+ T cells isolated from OT1 mice with the same 
C57BL/6 background and stained with CFSE should be co-cultured with the DCs to 
investigate their ability to prime T cells. Expansion of this specific transgenic OT1 CD8+ 
T cell against the agonist OVA, will substantiate the ability of the polymers to deliver 
functional antigen and prime an immune response.  
Primed CD8+ T cells can be further tested for their cytotoxic functionality against 
cells that display the delivered antigen. Several cell lines can be purchased that display the 
OVA on their surface providing a model for how well the T cells are primed ex vivo. OT1 
CD8+ T cells that have been expanded against the DCs treated with the antigen-agonist-
polymer complexes could be co-cultured with a mouse cell line expressing OVA that has 
either been stained or loaded with chromium. As the CD8+ T cells function as cytotoxic 
killer cells against their target, chromium or dye will be released into the media and can be 
measured either by radio isotopes or by flow cytometry respectively. High levels of cell 
death will indicate that the T cells have been sufficiently primed against the OVA target 
and are capable of providing an effective immune response against cell displaying the 
target antigen.  
Additionally, delivering other types of antigens and adjuvants by PTDMs into 
APCs could be explored to ensure that they system translates to other cargos. Examples of 
antigens that have readily available transgenic CD8+ T cell receptor models include gp100 
and MUC1. Along with new antigens, several other adjuvants are being developed for 
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clinical applications including TLR7 agonists and cytosolic danger signals that will 
stimulate the STING pathway. New agonists, or a mixture of agonists may improve the 
inflammatory response against the desired antigen and could easily be incorporated into 
future work at any stage. Lastly, cytosolic signals to promote tolerance could also be 
delivered into APCs to, causing otherwise active T cells to become senescent in the case 
of autoimmunity.  
The ultimate test of T cell priming would be to put the expanded T cells and DCs 
back into an animal model with a tumor expressing the delivered antigen. If there were 
stabilization or reduction in tumor size, it would confirm the robustness of the DC vaccine. 
There are still many things to be optimized before these experiments could be achieved. 
Further resources would be required in the form of collaboration to support animal studies. 
Specifically, a group interested in the interface of oncology and immunity would provide 
the support required to carry out such extensions of these PTDM delivery systems.  
Overall, the PTDMs discussed here have demonstrated delivery of functional cargo 
into a variety of cell types. Synthetically, the scaffold allows for tuning of molecular 
architecture for probing structure activity relationships in terms of both membrane and 
protein interactions. Additionally, functional protein delivery remains a largely uncharted 
territory, rich with application regarding fundamental understanding of molecular 
pathways. PTDMs provide many opportunities for future research at the materials 
immunology nexus.  
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